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Abstract
A retrospective study of Staphylococcus aureus bacteraemia in a provincial hospital in 
northeast Thailand established that S. aureus was responsible for considerable morbidity 
and mortality. A prospective study of 270 patients with invasive S. aureus infection in the 
same hospital showed that the range of clinical manifestations was broad and comparable 
to that in developed countries. All-cause and S. aureus-attributable mortality rates were 
26% and 20%, respectively. Multiple logistic regression analysis revealed that age, 
underlying cardiac disease and respiratory infection were risk factors for all-cause and S. 
aurei/s-attributable mortality, while abscesses and procedures for infectious source 
control were associated with survival. Patients infected by Panton-Valentine Leukocidin 
(PVL) gene-positive isolates had a strong survival advantage compared with patients 
infected by PVL gene-negative isolates. Evaluation of the patient sub-set with 
bacteraemia (n=98) demonstrated that the prevalence of endocarditis was similar to 
developed countries (14%), but that the all-cause and attributable mortality rates were 
considerably higher (52% and 44%, respectively). Methicillin-resistant S. aureus (MRSA) 
was responsible for 28% of bacteraemias, all of which were healthcare-associated. MRSA 
were multidrug resistant, and the proportion of MRSA-infected patients with bacteraemia 
prescribed an effective antimicrobial prior to culture results becoming available was low 
(15%). A subset of 73 patients with severe sepsis due to S. aureus bacteraemia was 
examined to consider why death occurred and how, by drawing on the ‘Surviving Sepsis 
Campaign’ guidelines, these might be prevented. Key findings were that the core 
elements of the guidelines were within the current resource capability of the hospital. A 
prospective study of rates of MRSA carriage and acquisition in 2 intensive care units 
demonstrated high rates of transmission and low compliance with hand-washing. In 
summary, S. aureus disease is an important pathogen in provincial Thailand and is 
probably responsible for a significant burden of disease across resource-restricted Asia.
Chapter 1. Introduction
1.1 Staphylococcus aureus disease
Staphylococcus aureus is a Gram-positive bacterium that can both colonise and infect 
animals and humans. It is well established as a major cause of community-acquired and 
nosocomial infection in developed countries.1'6 A review of bacteraemias in England and 
Wales between 1990 and 1998 found that S. aureus was the second most common cause 
annually after Escherichia coli and one of the top five causes in every age group.3 In the 
USA, S. aureus was the leading cause of hospital-acquired pneumonia and surgical site 
infections, and the second most common cause of nosocomial bacteraemia (after 
coagulase-negative staphylococci) during the period 1990 through 1992 according to data 
from the National Nosocomial Infections Surveillance system of the Centers for Disease 
Control and Prevention.7 In sharp contrast to wealthy developed countries, S. aureus 
disease ranks low on the public health agenda of resource-restricted countries in the 
developing world. S. aureus disease in these settings is perceived as trivial in terms of 
morbidity and mortality compared with other infectious diseases such as malaria, 
tuberculosis, HIV and pneumococcal infections. On closer inspection, however, the 
neglected status of S. aureus as a developing world pathogen does not equate with low 
rates of disease. This view is based on an evaluation of the growing body of literature on 
S. aureus disease originating from low income and lower middle income countries in 
South and East Asia comprised in large part of retrospective studies or case reports, but 
including several recent prospective studies.8'11
All of the work described in this thesis was focused on and performed in Thailand. 
In order to place this work in context, the literature reviewed covers the different features 
of S. aureus disease and carriage in resource-restricted South and East Asia, and is 
compared and contrasted with developed countries. Asia is the largest and most populous 
continent comprised of a patchwork of developed and developing countries in close 
proximity. Study of this region, therefore, serves as a useful proxy for understanding 
staphylococcal disease worldwide. Countries included in this literature review as resource-
restricted are those classified by the World Bank as being low income or lower middle 
income on the basis of gross national income (GNI) per capita.12 The countries included 
are Afghanistan, Bangladesh, Bhutan, Cambodia, China, India, Indonesia, Lao People’s 
Democratic Republic (Lao PDR), Maldives, Mongolia, Myanmar (Burma), Nepal, North 
Korea, Pakistan, Philippines, Sri Lanka, Thailand, Timor-Leste and Vietnam. Together, the 
3.37 billion inhabitants of these countries comprise more than half of the world’s 
population and account for over 70% of the 4.73 billion people worldwide who live in 
resource-restricted areas.13 The disparity in emphasis on S. aureus between these 
resource-restricted countries in South and East Asia and developed countries such as the 
UK, USA and Japan is highlighted in Figure 1.1.
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Figure 1.1: Comparison of the relative volume of published papers on S. aureus 
from resource-restricted countries in South and East Asia compared with Japan, 
the UK and USA.
mi—
CL
CL
O
Z
7000 
4000 
1000
500-r
i USAj  Japan 
UK
400*
300*
200*
100<
India
I
China
Thailand
i I-
1000 2000 3000 4000 5000 6000 7000 8000 30000 50000 
GNI per capita ($)
Each square represents one country. The countries clustered close to the x axis are 
Bangladesh, Bhutan, Cambodia, Indonesia, Lao People’s Democratic Republic (Lao 
PDR), Maldives, Mongolia, Nepal, Pakistan, Philippines, Sri Lanka, Timor-Leste and 
Vietnam. Since Afghanistan, Myanmar (Burma) and North Korea do not have gross 
national income (GNI) per capita data available on the World Bank website, they are not 
included on the graph; however, they all have 5 or fewer papers published on S. aureus 
disease.
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1.1.1 Epidemiology
Amongst the papers published on S. aureus disease from South and East Asia there is a 
notable predilection for the very young, neonates in particular. In the first reported blood 
culture study from Lao PDR, S. aureus was the most common cause of bacteraemia in 
children under one year of age.8 Examination of additional studies of S. aureus disease 
that included patients of all ages14"25 revealed that several confirmed this 
observation.14,15,20 A large number of studies described infection solely in neonates,2M8 
with some focussed on neonatal intensive care units,31,32,34 or special care baby 
units.40,44,45 These observations contrast with age-specific rates of invasive S. aureus 
disease in affluent nations, where invasive S. aureus disease has been reported to either 
increase with age49,50 or to reach maximal incidence at the extremes of age.51'53 However, 
it might be that S. aureus infection also occurs at a higher frequency in the elderly in 
resource-poor Asia, and that a possible reporting bias or age-related differences in the 
pattern of hospital referral or admission have resulted in under-representation of disease 
in this group. Alternatively, there may be increased availability of microbiological facilities 
in hospitals with neonatal care units or greater use of these facilities by neonatal care 
units, resulting in over-representation of neonates. Accurately defining the epidemiology of 
staphylococcal infection in many developing countries is hampered by significant 
variability in medical care, inadequate diagnostic microbiology facilities and lack of 
published studies.
1.1.2 Risk factors for disease
Risk factors for S. aureus disease in wealthy developed countries include nasal 
carriage,1,54’56 presence of invasive devices,1,2,50,55,57 surgical procedures1,55,57 and for 
methicillin-resistant S. aureus (MRSA), hospitalisation2,49,55 and antibiotic exposure.1,55,58 
In resource-restricted South and East Asia, medical devices59'61 or procedures62'64 and 
preceding antibiotic exposure65'68 have been identified as risk factors for the development 
of nosocomial S. aureus infection, but hospitalisation as a risk factor for MRSA 
colonisation and infection has been the subject of very few published studies.16,65
Available data including some limited molecular typing link MRSA with the hospital setting. 
Risk factors relating to S. aureus infection in neonates are poorly defined. Practices 
relating to umbilical stump care and vaccination may be involved, and a lack of infection 
control procedures and associated nosocomial infection have been described.43,47
1.1.3 Clinical manifestations
S. aureus is known to give rise to a wide range of superficial skin infections and deep 
infections affecting bones, joints, heart valves and solid organs in developed countries.1,69 
Although many studies from South and East Asia describe a single type or category of 
clinical presentation, the collation of this published work indicates that the range of clinical 
manifestations of S. aureus infection reported from resource-restricted Asia is as broad as 
that observed in other settings. These include bacteraemia,8,11,14,15,25,70'88 endocarditis,75,89' 
97 meningitis and brain abscess,20,23,33,63,70,98'101 pneumonia,59,86,102'123 empyema,104,124 
septic arthritis30,125'127 and osteomyelitis,30,127'129 abscesses of solid organs,130 
pyomyositis131'140 and skin and soft tissue infections.9,10,16,29,32,62,111,115,117,141'155 The 
overwhelming majority of published studies involving neonates relate to bacteraemia,26' 
28,31,33-35,37-41 jn c |u c | j n g  both early onset sepsis (variably defined as either within 48 hours,26 
within 72 hours27 or the first week of life),28,31 and late onset sepsis (more than 48 
hours,26,34 more than 72 hours27 or more than 1 week).28,31 Bacteraemia is also the most 
common presentation of serious infection reported in older children,8,11,14,15,25,71'76 although 
lower respiratory tract infections102'109 (including empyema)124 and endocarditis89'93 are 
also described. Despite the textbook focus on pyomyositis as the “tropical” form of S. 
aureus disease,156'158 there are just 10 studies describing pyomyositis in the literature from 
our target countries.131'140 Thus, S. aureus infection in resource-restricted Asia is not only 
common but frequently presents as invasive disease.
Once S. aureus bacteria are in the bloodstream they can disseminate throughout 
the body, which results in metastatic foci of infection at sites distant to the original source 
or point of entry.1 It can be very hard clinically to detect those patients with metastatic
infection. For example, Fowler et al demonstrated that amongst patients with S. aureus 
bacteraemia, predisposing heart disease and clinical findings did not differentiate those 
with and without infective endocarditis and that transoesophageal echocardiography was 
required.159 A further clinical challenge in those identified with complications is to then 
determine the course of infection in terms of primary site compared with metastatic foci. 
When an intravenous device is the source of infection for S. aureus bacteraemia, 
subsequent sites of infection identified are more likely to have seeded from the site of the 
initial intravenous device infection. As there is an on-going trend for an increasing 
proportion of S. aureus bacteraemias to result from intravenous devices,2,160 ascertaining 
clinical, imaging or laboratory tests to assist in identifying patients at greatest risk of 
metastatic infection becomes more pertinent. A study from the USA demonstrated that a 
scoring system based on the presence or absence of 4 risk factors (community 
acquisition, skin examination findings suggesting acute systemic infection, persistent fever 
at 72 hours, and positive follow-up blood culture results at 48 to 96 hours) accurately 
identified complicated S. aureus bacteraemia, with a positive follow-up blood culture being 
the strongest predictor.161 In intravenous catheter-related bloodstream infection, persistent 
fever and/ or repeated positive blood cultures after 3 days following intravenous catheter 
removal has been shown to predict complicated S. aureus bacteraemia.162
1.1.4 Mortality
It is not possible to determine the death rate for serious S. aureus infection from the 
studies published from resource-restricted Asia. The majority considered all-cause 
bacterial sepsis in which S. aureus disease represented a small subset and organism- 
specific outcomes were not detailed, although several studies did comment that infection 
with S. aureus carried an increased risk of death compared with other bacterial 
pathogens.91,113,163
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1.1.5 Drug resistance
Signalled by the acquisition of penicillin resistance in the 1940s,164 strains of S. aureus 
have since acquired resistance to methicillin (often in association with resistance to other 
antimicrobial groups including macrolides, aminoglycosides and quinolones),165,166 and 
more recently intermediate, followed by full resistance to glycopeptides.167,168 Methicillin 
resistance is acquired by insertion of the staphylococcal cassette chromosome mec 
(SCCmec) element, which carries the gene encoding an altered penicillin binding protein. 
SCCmec elements have been acquired on multiple occasions by biologically fit S. aureus 
clones circulating in the community.169'171 Penicillin resistance is now virtually ubiquitous 
and methicillin resistance is geographically variable but is approaching 50% for invasive 
isolates in many areas of Europe, America and Australia.172'174 The proportion of S. 
aureus blood culture isolates that are methicillin-resistant currently reaches 70% in 
affluent Asian countries such as Japan175 and South Korea,176 but rates of MRSA infection 
in less affluent Asian countries are generally poorly defined. Despite the perceived 
importance of MRSA and the large volume of research devoted to its study across the 
developed world, almost nothing is known about the emergence and transmission of 
MRSA in resource-poor regions of the world. Large-scale surveillance systems in Asia 
such as the SENTRY Antimicrobial Surveillance Program and ANSORP (Asian Network 
for Surveillance of Resistant Pathogens) focus for the large part on the more affluent 
countries,177'179 and isolate collections are inevitably biased towards areas that contain 
diagnostic microbiology facilities. Most studies describing MRSA rates involve sub-groups 
of patients, especially high-risk patients such as those with burns, from which meaningful 
conclusions on MRSA prevalence cannot be drawn. However, multi-centre MRSA 
surveillance data from China and India suggest that MRSA accounts for a considerable 
burden of disease in these countries.180'182 Additionally, data published from the National 
Staphylococcal Phage Typing Centre in India shows that MRSA rates rose annually 
during the 1990s.183
Given the patchwork nature of the available data on MRSA, the prevalence of 
MRSA infection across large areas of resource-restricted Asia is unknown but may be
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considerable, if extrapolations are made from the information that is published. The 
dissemination of MRSA across low-income regions would have major implications for the 
antibiotic treatment of, and outcome from serious S. aureus disease. MRSA infection is 
likely to go unnoticed as a consequence of the widespread lack of diagnostic microbiology 
facilities, leading to the probability of ineffective antibiotic prescribing and an inevitable 
increase in the rate of poor outcome.184'186 As elsewhere in the world, serious MRSA 
infection in Asia requires treatment with glycopeptides, but these relatively expensive 
antibiotics are of limited availability across low-income settings and require administration 
by intravenous injection. Furthermore, optimal glycopeptide dosing requires monitoring of 
serum drug levels, a capability which is usually lacking.
1.1.5.1 Community-acquired MRSA
MRSA was initially a problem limited to hospital-adapted isolates but has now extended to 
arise de novo in community isolates.187'190 Community-acquired (CA-) MRSA carry novel 
SCCmec elements.191,192 This has spawned a plethora of research in the developed world 
and initiated much discussion over the challenges posed for antibiotic prescribing.193'194 
Classification of CA-MRSA varies in the literature but at its most basic requires that there 
has been no contact with healthcare facilities, usually for at least 1 year. There are very 
few studies from resource-restricted Asia describing MRSA infection in the absence of 
contact with healthcare facilities.16,124,144 In these reports, putative CA-MRSA (as defined 
by lack of hospital contact) accounted for 3-11% of S. aureus infections: 3 CA-MRSA from 
88 S. aureus isolates associated with empyema thoracis (3%);124 6 CA-MRSA from 116 S. 
aureus isolated from varied pus samples (5%);144 and 22 CA-MRSA from 202 S. aureus 
pyoderma (11%).16 This suggests that CA-MRSA is beginning to emerge but its true 
prevalence is not known. These studies did not apply the molecular tools commonly used 
to characterise MRSA, such as SCCmec typing (which is usually type IV or V for CA- 
MRSA), pulsed field gel electrophoresis (PFGE) or multilocus sequence typing (MLST).
Over-the-counter antibiotics, such as penicillins (including cloxacillin), 
cephalosporins, tetracyclines, quinolones and trimethoprim-sulfamethoxazole, are readily
available from pharmacists across much of Asia and these are frequently self­
administered for inappropriate indications, and taken for irregular durations.195'197 The cost 
of ten tablets of cloxacillin purchased over the counter from a pharmacy in provincial 
Thailand in 2007 was around £1 ($1.80 at 2007 exchange rates), and the cost of 10 
tablets of amoxicillin, doxycycline or ciprofloxacin was around 85 pence ($1.50) (personal 
experience). This uncontrolled antimicrobial use is likely to fuel the emergence of CA- 
MRSA as well as drug resistance in a broad range of other human pathogens. Sub­
standard antibiotics are commonly reported from resource-restricted Asia,198 the presence 
of which could further drive resistance.
1.1.5.2 Vancomycin resistance
Reduced susceptibility to vancomycin was first described from Japan.168,199 Since then full 
resistance to vancomycin has been reported from the USA200"202 and Tehran,203 and 
intermediate resistance from Belgium,204 Brazil,205 France,206 Korea,207 Portugal,208 
Scotland209 and South Africa.210 Given that vancomycin is the mainstay of treatment for 
MRSA, the emergence of glycopeptide resistance is of great concern, although it is 
currently uncommon in developed countries.211'213 Amongst the resource-restricted 
countries of Asia, full resistance to vancomycin has been reported from India in an 
evaluation of 783 clinical S. aureus isolates collected between August 2002 to July 
2005.214 Two isolates were vancomycin resistant (minimum inhibitory concentration (MIC) 
32 pg/ml and MIC 64 pg/ml, respectively) and 6 isolates had intermediate resistance (MIC 
16 pg/ml for 2 isolates and MIC 8 pg/ml for 4 isolates) as defined by agar dilution. None of 
these isolates was positive by polymerase chain reaction (PCR) for vanA. The gene vanA 
encodes resistance to vancomycin in vancomycin-resistant S. aureus (VRSA) and is likely 
to be acquired from vancomycin-resistant enterococci (VRE). However, the reduced 
susceptibility seen in vancomycin-intermediate S. aureus (VISA) is not mediated by the 
van genes, but is associated with a marked thickening of the cell wall.215 A further VRSA 
(MIC >64pg/ml) has been isolated from the pus specimen of an out-patient in Kolkata, 
India in 2005, which was positive for var?A.216
Heterogeneous vancomycin-intermediate S. aureus (hetero-VISA) refers to an 
isolate with a sub-population of colonies demonstrating intermediate resistance to 
vancomycin. A study of isolates collected by ANSORP reported the isolation of hetero- 
VISA from India (5 isolates, 6.3% of all Indian MRSA tested), Thailand (2 isolates, 2.1%), 
Vietnam (1 isolate, 2.4%) and the Philippines (1 isolate, 3.6%).179 A further 4 hetero-VISA 
have been reported from Thailand.75,217 The majority of other studies evaluated in this 
review used a disk diffusion method for detection of vancomycin susceptibility, an 
inaccurate method for the assessment of intermediate resistance.212 Although isolates 
with reduced susceptibility to vancomycin have been identified in my target countries, they 
remain uncommon at present.
1.1.6 Bacterial typing
S. aureus epidemiology has relied extensively in recent years on the use of MLST to 
define bacterial population genetic structure. Studies of MRSA including isolates from my 
target countries have demonstrated a predominance of sequence type (ST) 239 (SCCmec 
type III or IIIA) and ST 5 (SCCmec type II or IV).218,219 A study of 74 MRSA isolates from 
12 Asian countries (5 or 6 isolates from most countries) collected between 1998 to 2003 
found that most isolates from South Korea and Japan were ST 5, whereas ST 239 
predominated in the other Asian countries including China, Indonesia, India, Philippines, 
Sri Lanka, Thailand and Vietnam.218 A subsequent study from South Korea suggested that 
ST 239 had recently emerged there.220 Further studies have confirmed the predominance 
of ST 239 in China, India, Mongolia and Thailand.221'225 A study conducted in China of a 
selected group of MRSA isolates (selected on the basis of positivity for genes encoding 
Panton-Valentine Leukocidin) reported equal numbers of ST 88, ST 239 and ST 398.226 
The utility of typing in a developing country setting was demonstrated by a report 
describing the investigation of an outbreak of MRSA infection in Vietnam that was 
associated with vaccination.227 S. aureus of an identical genotype was isolated from 
injection site abscesses of 4 children, and nasal and throat swabs from their vaccinator,
10
typing of which demonstrated that they were SCCmec type V (or type 5C) and ST 59, the 
endemic CA-MRSA clone in Taiwan.228
Non-governmental organisations and hospitals reliant on overseas volunteer 
healthcare staff are at risk of MRSA being introduced by one or more individuals from 
settings where MRSA carriage occurs. A study from Lao PDR reporting the first isolation 
of MRSA in the country highlighted this potential problem. Molecular typing demonstrated 
that the SCC mec type of the isolate in question matched the type carried by CA-MRSA 
isolates in Japan.117 The hospital from which it was isolated received many Japanese 
exchange staff, raising the possibility of international spread by medical staff. This 
highlights the importance of several approaches in resource-restricted settings to identify 
the emergence of MRSA and understand routes of MRSA transmission, including the 
screening of healthcare workers prior to arrival, ongoing vigilance, and the judicious use of 
molecular techniques. It is also likely that overseas staff can become colonised with 
MRSA during work in low-income countries and return to hospitals in developed countries 
with these isolates.
1.1.7 Staphylococcal toxins
S. aureus can produce a number of different toxins that give rise to specific diseases.1 
Enterotoxins (staphylococcal enterotoxins A to E) can result in the development of 
gastroenteritis and toxic shock syndrome toxin 1 (TSST-1) causes toxic shock syndrome. 
The exfoliative toxins, epidermiolytic toxins A and B, induce separation of the skin layers 
to produce scalded skin syndrome. Although a rare condition, toxic shock syndrome 
became widely known in the early 1980s when an increase in the number of cases was 
related to menstruation and the use of hyper-absorbent tampons in countries where 
tampon use is common, particularly North America and western Europe.229'232 These 
toxin-induced manifestations of S. aureus disease are also reported from resource- 
restricted countries in South and East Asia. Gastroenteritis arising from staphylococcal 
enterotoxins has been reported from India,24,233-236 the Philippines237 and Thailand238 and 
staphylococcal enterotoxins found in a variety of clinical samples in Sri Lanka.239
Published reports of toxic shock syndrome from my target countries are all non-menstrual 
and include paediatric cases,240 following vaccination241 and pyogenic skin infections in 
India;242,243 and vaginal infection in China.244 A study of scalded skin syndrome has been 
published from China,245 as have case reports from India246 and Thailand.247
1.1.7.1 Panton-Valentine Leukocidin
Panton-Valentine Leukocidin (PVL) is a bicomponent leukocytotoxin and putative 
virulence factor. Since the first clinical study describing an association between PVL and 
necrotising pneumonia in young adults was published,248 interest in PVL as a virulence 
determinant for human infection has grown at a staggering speed, fuelled in part by the 
finding that many emergent community-acquired MRSA isolates are PVL gene-positive.249' 
251 The evidence for PVL as a virulence determinant in animal models is mixed and 
controversy abounds. Some studies are supportive,252'255 whilst others convincingly cast 
doubt on PVL being a virulence determinant.256'259 The leukolytic effect and hence lethality 
of PVL on mouse neutrophils has been shown to be less than that on human 
neutrophils,260,261 which calls into question the results from mouse-based disease models 
for PVL pathogenesis. Additionally, despite finding a 10-fold variation in the amount of 
PVL produced by disease-causing isolates, there was no correlation between quantity of 
PVL and disease severity.262 Recent studies have elucidated that pathogenesis previously 
ascribed to PVL may in fact relate to other toxins, such as alpha-haemolysin259 and novel 
phenol-soluble modulin peptides,263 or disruption of a global gene regulator of S. aureus 
that controls the expression of multiple virulence determinants.264
In the developed world carriage of the genes encoding PVL is associated with skin 
and soft tissue infections265'269 as well as with more serious infections such as severe 
necrotising pneumonia.248,266,270"272 The clinical studies on PVL often describe selected 
sub-groups of patients,248 case reports270'273 or S. aureus isolates sent to a reference 
laboratory266,274 creating a disproportionate emphasis on the severe end of the disease 
spectrum, namely necrotising pneumonia. PVL gene-positive S. aureus in resource- 
restricted countries in South and East Asia have also been associated with skin and soft
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tissue infections,226,227,275,276 together with a single reported case of fatal necrotising 
pneumonia.277 Data on the proportion of S. aureus isolates positive for PVL in South and 
East Asia is sparse and only available for a small number of countries. PVL has been 
detected in 7.2% to 13.3% of disease-associated S. aureus isolates in China226,278'280 and 
PVL positivity of methicillin-sensitive S. aureus (MSSA) carriage isolates in Indonesia was 
reported as 10.6%.281
Interest in PVL as a virulence determinant has prompted the development of rapid 
tests for the earlier detection of the genes encoding PVL. At the time of writing there have 
been 2 multiplex PCR tests created for this purpose282,283 and proof of concept for a 
method involving matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry.284
1.1.8 Management of S. aureus disease
The management of S. aureus disease requires consideration of antibiotic therapy, 
infectious source control and general supportive care for sepsis tailored to the specific 
disease manifestation and its severity. Each of these aspects of management is 
discussed in turn.
1.1.8.1 Antibiotic therapy
Antibiotic therapy is the mainstay of treatment for S. aureus disease, with the route of 
administration (topical, oral or intravenous) reflecting the severity of infection. For MSSA 
infections, penicillinase-resistant beta-lactams are the drug group of choice,1,285,286 for 
example flucloxacillin, cloxacillin and nafcillin, depending on the drug supplied in different 
countries. Patients with a penicillin allergy should be treated with a non-beta-lactam 
antibiotic, such as erythromycin, or a cephalosporin if the allergy is minor (e.g. skin rash) 
since up to 10% of patients with a penicillin allergy have a cross-reaction with the 
cephalosporin group of antibiotics.287,288 Since penicillin resistance exceeds 95% 
worldwide, penicillin can only be used for patients infected with an isolate proven to be 
sensitive with in vitro susceptibility testing. First and third generation cephalosporins (e.g.
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cefazolin and ceftriaxone, respectively) and carbepenems (e.g. meropenem) are also 
effective for MSSA infections, but first generation cephalosporins may not be as effective 
for severe infections such as endocarditis.285 In serious invasive MRSA infections, such as 
bacteraemia or pneumonia, vancomycin is the first line drug of choice.1,285,286 However, 
there are concerns with vancomycin use including the development of tolerance and 
resistance, poor tissue penetration and slow bactericidal activity, which is leading to 
increased use of newer alternative antibiotics.289 The newer anti-MRSA antibiotics include 
linezolid, daptomycin, tigecycline, dalbavancin, ceftobiprole and iclaprim,290-293 but these 
are expensive. For MRSA infections that are amenable to oral antibiotic therapy, such as 
skin and soft tissue infections, the choice of lincosamines (e.g. erythromycin, 
clindamycin), fluoroquinolones (e.g. ciprofloxacin), tetracyclines (e.g. doxycycline), 
trimethoprim-sulphamethoxazole or rifampicin and fusidic acid in combination depends on 
local susceptibility patterns for MRSA infections. In Thailand, a wide range of standard 
antibiotics are readily available, including over-the-counter in pharmacies; however, the 
newer anti-MRSA antibiotics are not obtainable (personal experience). Vancomycin is 
prescribed in Thailand but the facilities to monitor drug levels to lessen the risk of toxicity 
are limited and not available in most hospitals.
Delays in receiving effective antibiotic therapy are known to have a deleterious 
effect on outcome from S. aureus bacteraemia in developed countries.184-186 For 
appropriate antibiotic therapy to be timely, the choice of empirical antibiotics needs to 
predict the most likely bacterial causative agents based on local disease patterns and 
susceptibility profiles. Therapy can then be narrowed once culture results are available. 
Where background rates of MRSA are high, vancomycin is used for surgical prophylaxis 
and as empiric therapy for suspected S. aureus infection in order to prevent the 
inadvertent treatment of MRSA infection with cloxacillin, which is associated with a poor 
outcome. The down side is that a high rate of vancomycin usage drives the emergence of 
resistance and increases drug costs. Studies specifically addressing the timing of 
antibiotic therapy for S. aureus infection have not been reported from South and East 
Asia.
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1.1.8.2 Infectious source control
Abscess formation is a common finding in S .aureus disease.1 These collections of pus 
can develop locally at the portal of entry or in diverse locations around the body following 
haematogenous spread. In general, antibiotics alone are not sufficient to resolve deep pus 
collections and drainage is required.294 A drainage procedure without effective antibiotic 
therapy for localised skin and soft tissue abscesses can be sufficient to achieve 
cure.268,295,296 In developed countries, the presence of an uneradicated focus of infection 
has been associated with a 6.7 times increase in mortality;297 and failure to remove an 
intravenous catheter in nosocomial bacteraemia resulted in a 6.5 times increase in death 
or relapse of infection 298 In developing countries in South and East Asia, there is minimal 
information regarding the effect on outcome resulting from the active management of pus 
collections in S .aureus disease. A study from India discusses the differing management 
approaches to empyema thoracis;124 another study from India concludes that needle 
aspiration is an effective alternative treatment to an open drainage procedure for pyogenic 
liver absceses;130 and surgical drainage for iliopsoas abscesses is recommended as a 
cost-effective primary treatment in a study from Nepal.140
1.1.8.3 Supportive Sepsis Care
By standard sepsis definitions,299'301 sepsis is a systemic inflammatory response 
syndrome (SIRS) resulting from the presence of infection; severe sepsis is SIRS with 
organ dysfunction, hypoperfusion or sepsis-induced hypotension; and septic shock is 
SIRS with sepsis-induced hypotension despite adequate fluid resuscitation. These terms 
represent increasing severity along a pathological continuum; as a patient progresses 
from sepsis through severe sepsis to septic shock their risk of dying increases.302,303 
Severe sepsis and septic shock are estimated to affect millions of people each year and 
are important causes of mortality worldwide.304'310
Early recognition of sepsis and prompt resuscitation are paramount to achieving a 
successful outcome.311 Two critical components of the initial sepsis care are early fluid
15
resuscitation, with the first 1 to 6 hours having the greatest impact on outcome;312'314 and 
timely administration of effective antibiotic therapy, ideally within the first hour as each 
hour delay over the next 6 hours after that has been shown to result in a 7.6% decrease in 
survival.315 Given the vascular dilatation and leakage of plasma into the extravascular 
space that occurs in sepsis,316 aggressive fluid resuscitation involving large volumes is 
necessary, and vasopressors and inotropes may be required in addition to maintain an 
adequate blood pressure.311 Despite the recommendations for fluid resuscitation in the 
initial hours of sepsis, an audit of paediatric sepsis care in the UK showed that 62% of 
children received inadequate fluid resuscitation and inotropic support,317 and an audit of 
adult care found that nearly half the patients did not receive an adequate fluid 
challenge.318
The other aspects of supportive sepsis care depend on the specific organ 
dysfunction developed by the patient. Respiratory dysfunction frequently complicates 
sepsis and requires ventilatory support.319'321 However, mechanical ventilation can also 
lead to considerable additional morbidity, such as ventilator associated pneumonia,322,323 
and acute lung injury if tidal volumes are too high.324 Tidal volume control can be 
particularly challenging in resource-restricted developing countries where less 
sophisticated ventilators are used that may not facilitate fine tuning of tidal volumes or 
control of inspiratory pressures. Renal replacement therapy plays an important role in 
sepsis management for the treatment of acute renal failure and acidosis. In developed 
countries, haemodialysis is used in the setting of acute sepsis but in resource-restricted 
developing countries peritoneal dialysis may be the only available option. A study from 
Vietnam demonstrated the superiority of haemodialysis over peritoneal dialysis for acute 
infection-related renal failure.325 Since critical illness-related corticosteroid insufficiency 
can affect patients with severe sepsis, physiological corticosteroid replacement is 
currently recommended in patients with vasopressor-dependent septic shock.326,327 The 
use of insulin to achieve tight glycaemic control is controversial. Tight glycaemic control 
reduced the mortality of cardiac surgical intensive care patients328 but only improved 
morbidity not mortality in a medical intensive care setting.329 A meta-analysis of intensive
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insulin therapy in critically patients did find a survival benefit,330 although it should be 
noted there were no medical intensive care units included. Excess hypoglycaemic 
episodes in patients receiving intensive insulin therapy331 means that this is unlikely to be 
suitable for developing country settings where staffing levels may be lower. Activated 
protein C provides a survival advantage in patients with severe sepsis and at high risk of 
death (more than one organ dysfunction) but there is a considerable bleeding risk332,333 
and is too expensive for widespread use in developing countries. Additional adjunctive 
therapies include deep vein thrombosis prevention334,335 because the critically ill are at a 
higher risk of deep vein thrombosis336 and stress ulcer prophylaxis because patients with 
severe sepsis often have risk factors identified for gastrointestinal haemorrhage in the 
critically j||.337-338
The ‘Surviving Sepsis Campaign’ international guidelines for the management of 
severe sepsis and septic shock were first published in 2004339 and then updated in 
2008.340 These guidelines are highly influential documents that describe best practice in 
resource-rich settings, and represent an important milestone in the improvement of 
standards of clinical care in the developed world. However, the majority of deaths arising 
from sepsis worldwide most likely occur in developing countries because of the huge 
burden of bacterial infections and resource-restriction in these regions.341 Bacterial 
infections are implicated as the direct cause of death from lower respiratory infections, 
meningitis, and a range of other infections342'345 and also complicate other common 
diseases such as malaria, HIV/AIDS and diabetes mellitus.346'348 Although understudied, 
severe sepsis is associated with extremely high mortality rates in developing countries 
worldwide,321,349,350 and in South and East Asia.351 The facilities and therapeutics available 
for the medical care of patients with sepsis throughout the developing countries of South 
and East Asia are highly variable, and a scaled approach to management based on 
optimising utilisation of existing resources has been suggested which could represent a 
practical and flexible strategy.341
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1.2 S. aureus carriage
The epithelial surfaces of humans are colonised by bacteria that constitute the commensal 
flora, including the gastrointestinal and respiratory tracts. S. aureus is commonly found as 
part of the flora.1,56 Colonisation occurs very early in life: S. aureus has been grown from 
the umbilical stump and groin within a day of birth and subsequently from the nose.352,353 
The predominant site of S. aureus carriage is in the anterior nasal passages,56,354,355 but S. 
aureus colonisation has also been reported from multiple other sites around the body 
including the throat, axilla, groin, rectum and in skin and soft tissue wounds in developed 
countries.56,354 Studies of S. aureus carriage from developed countries demonstrate that 
colonisation is dynamic: there are changes with increasing age354'358 and over time for the 
population.56,359 Children carry S. aureus more frequently than adults354,355,358, typically 
with those less than 8 weeks old having the highest colonisation rates and decreasing 
thereafter354,356"358 although a normal distribution with a peak at 11 years of age has also 
been described;360 and persistent carriage gives way to intermittent carriage typically 
between the ages of 10 and 20 years.355 The decrease in S. aureus carriage over the last 
70 years is thought to reflect improvements in personal hygiene56 and socioeconomic 
status361 and decreased family sizes.360 In developed countries studies of S. aureus 
colonisation have shown that about 20% (range 12-30%) of the general population are 
persistent S. aureus nasal carriers and approximately 30% are intermittent carriers (range 
16-70%).56,359 Some of the variation between intermittent carriage and persistent carriage 
rates in different studies is dependent upon the length of follow-up and the definitions for 
determining each category.56,359,362,363 Additionally, colonising isolates of S. aureus within 
the nose vary over time.363,364 Those people who have been hospitalised or require regular 
out-patient care are at an increased risk of carrying MRSA rather than MSSA.365,366 In 
addition, with the worldwide emergence of community-acquired MRSA there is an 
increasing likelihood that people with no healthcare contact may be colonised with 
MRSA.367,368
Currently there is a single paper with details of S. aureus carriage from 
Thailand,369 which was detected as part of an MRSA outbreak in a burns unit and minimal
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studies focusing on colonisation with S. aureus from South and East Asia. These include 
3 months surveillance for MRSA carriage amongst patients and staff on a surgical unit in 
Sri Lanka;370 a further study from Sri Lanka describing the prevalence of and risk factors 
for nasal colonisation with MRSA of those admitted to a surgical unit;65 work determining 
the prevalence of MRSA amongst a random sample of children in the community in 
Nepal,371 a study reporting the high prevalence of S .aureus colonisation, including MRSA, 
of burn wounds in China;372 MRSA surveillance studies in India involving healthcare 
workers,373'375 patients374 and healthy volunteers375; and a study demonstrating the 
effectiveness of nasal mupirocin to eradicate S. aureus carriage and thereby prevent 
catheter exit site infections and peritonitis in peritoneal dialysis patients in India.376
1.2.1 Relationship of carriage to infection
The importance of carriage is that the majority of patients who develop invasive S. aureus 
disease are infected with the strain with which they are colonised.54,56,377'379 This has been 
demonstrated in a variety of clinical settings including the development of post-operative 
wound infections,380,381 following peritoneal dialysis379 and haemodialysis377 and in those 
with human immunodeficiency virus (HIV).378,382 Additionally, rates of S. aureus infection 
are higher in those who are colonised with S. aureus than in non-carriers.377,379,380,382,383 As 
a consequence of this close relationship between colonisation and infection, eradication of 
colonising S. aureus, principally nasal carriage, is used as a strategy to prevent 
subsequent infections in high risk patients and when the outcome could be devastating, 
for example in those requiring dialysis377,384,385 or undergoing major surgery,386'388 
especially surgery involving prosthetic material.389
1.2.2 Patterns of S. aureus carriage
The highest detection of S. aureus carriage is in the anterior nasal passages,56,354,355 
followed by the perineum and throat.354,355,390'392 Lower rates of detection are found from 
the gastrointestinal tract, vagina and axillae.393'396 People who are nasal carriers of S. 
aureus have higher rates of colonisation with S. aureus at other sites around the body
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than the general population.56,354 Rates of carriage of S. aureus are higher in patients 
undergoing regular venepuncture, such as those requiring dialysis,377,379 or in patients 
needing regular injections, such as diabetics managed with subcutaneous insulin,397 or in 
those who inject drugs recreationally.398 Intravenous devices such as cannulas and cut- 
downs provide colonising bacteria with a route of entry to the body and 
bloodstream.56,399,400 In Intensive Care Units the increased use of invasive interventions 
and monitoring means that patients are more vulnerable to developing hospital-acquired 
infections.399,401'404 In hospitals where MRSA is endemic the risk of infection with MRSA 
increases with the length of stay.401,403,405 Many countries routinely swab patients in high- 
risk areas, such as intensive care units, in order to detect MRSA colonisation before the 
development of infection.406^ 10 The sites chosen for sampling are very variable,401,405,411'415 
as yet there is no consensus on best practice. Screening for MRSA is typically performed 
weekly 401,414,416 Actively screening patients at high risk of MRSA, for example those 
previously colonised or infected, residents of nursing homes, those admitted to a 
healthcare facility in the preceding 12 months, those receiving recent antibiotic therapy 
and patients transferred from another hospital,406,417'419 forms the essential foundation for 
infection control.406
1.3 Infection control
Infection control relates to the prevention of nosocomial transmission of multi-resistant 
organisms within a healthcare facility. In developed countries, infection control policies are 
implemented in relation to patients colonised or infected with MRSA aiming to prevent the 
spread of MRSA to other patients.406,409,410 In general a whole package of infection control 
measures are put in place together.409,420,421 There are universal infection control 
measures such as hand hygiene, barrier nursing, isolation and cohorting and other 
measures specific to MRSA, for example de-colonisation.
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1.3.1 Hand hygiene
Studies from developed countries have highlighted the hands of medical staff as an 
important route of transmission for hospital-acquired infections, including MRSA.420,422-426 
There is an association between nasal MRSA colonisation and the carriage of MRSA on 
hands,56,427,428 with nasal colonisation thought to reflect longer term carriage.56 There is a 
linear relationship between the length of time providing care and bacterial contamination 
of the hands of healthcare workers 425,429 Direct patient contact, respiratory care and 
contact with body fluid secretions in adults429 and skin contact, nappy change and 
respiratory care in neonates430 are associated with higher rates of bacterial hand 
contamination in healthcare workers. The use of gloves significantly reduces bacterial 
contamination of the hands 429,431 even when leaks occur.432 Although there is a 
consensus on the benefit of cleaning hands of healthcare workers in reducing rates of 
nosocomial infection 425,433,434 findings on the relative superiority of available agents for 
hand cleansing differ. Some studies demonstrate improved outcome with hand washing if 
an antimicrobial agent such as chlorhexidine is used,435 and others find alcohol gel more 
effective.429,431 However, irritant contact dermatitis and eczema as a result of frequent and 
vigorous hand washing with anti-septic agents can result in broken skin and increased 
shedding of micro-organisms.434 Use of alcohol gel can increase hand cleansing 
compliance above that for hand washing with soap and water436 likely due to its being 
easier to use and less time consuming. Intervention studies assessing the changes in 
nosocomial infections rates with hand hygiene programmes generally report a reduction in 
infection rates 437-441 although not all reach significance.442,443
Studies specifically addressing hand hygiene in resource-restricted South and 
East Asia are limited. Adequate hand washing is impeded in developing countries by a 
lack of basic resources such as soap and alcohol gel, as has been reported from 
Afghanistan and Cambodia;444 or lack of hand wash basins as detailed from 
Indonesia.445,446 Hand washing compliance remained poor even when soap and alcohol 
gel were readily available in a study from India.447 In Bangladesh, an intervention study 
that included hand hygiene amongst other infection control measures demonstrated a
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reduction in the number of nosocomial infections in a special baby care unit.448 In 
Indonesia 2 different intervention studies both involving a combination of installing hand 
washing facilities and an education programme to promote hand washing increased hand 
washing compliance rates on the study wards.445,446 In the Philippines a study evaluating 
the interventions of providing alcohol hand gel, workshops on hand hygiene and a daily 
checklist of infection control aspects of care on 2 neonatal intensive care units found that 
whilst there was an improvement in hand washing compliance during the intervention 
period of the study compared with the previous observation period, the rates of 
colonisation with antibiotic resistant organisms, including MRSA, did not change 
significantly.449 A study reporting good hand hygiene compliance was published from 
Pakistan involving anaesthetists in a tertiary care hospital.450
1.3.2 Barrier nursing
Barrier nursing involves the use of gowns, gloves and masks for patient care and 
interaction with the patient’s environment. These are recommended to prevent the 
patient’s blood or bodily fluids coming into contact with the healthcare worker.406,451,452 
There are less data on barrier nursing than hand hygiene from the target countries. Two of 
the studies assessing hand washing compliance additionally investigated barrier nursing: 
one of the intervention studies from Indonesia also monitored the usage of gloves, gowns 
and masks and demonstrated that appropriate compliance was low, however overuse 
when not indicated was common;446 and the report published from Pakistan involving 
anaesthetists in a tertiary care hospital found good compliance with glove usage as well 
as hand hygiene.450
1.3.3 Isolation and cohorting
Infection control guidelines from developed countries recommend either isolating patients 
with MRSA or cohorting them to prevent further transmission of MRSA.406,452 Isolation 
refers to a single room whereas cohorting involves grouping patients with MRSA in a bay 
or geographically distinct area within a ward. In south-eastern Mediterranean hospitals
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over-crowding and lack of isolation beds, especially in the context of high bed occupancy 
rates, have been demonstrated to result in higher prevalence rates of MRSA carriage.453 
However, a study conducted in 2 Intensive Care Units in London did not find a benefit 
from cohorting or isolating patients with MRSA 454 There is a single paper published from 
South and East Asia relating to cohorting of patients. It involves an infection control 
intervention study performed in a special care nursery in Bangladesh which included 
cohorting neonates with surgical wound infections as well as carrying out other infection 
control measures, such as hand hygiene promotion, and found that infection rates were 
reduced following the interventions.448 The relative contribution of cohorting is not 
commented on.
1.3.4 Decolonisation
In certain circumstances, such as prior to major surgery involving prosthetic material, 
patients are decolonised of their MRSA in order to prevent subsequent infection.406'455 
Decolonisation may also be used to help control an outbreak of MRSA.406 Typically 
decolonisation comprises nasal and skin decolonisation, which entails topical mupirocin 
applied to the anterior nasal passages 3 times a day for a 5 day course and washing with 
an antiseptic, such as chlorhexidine or povidine iodine, for 5 days.406 Mupirocin should 
only be used for short courses in order to prevent the development of resistance,406 hence 
when it is used in dialysis patients to prevent peritoneal catheter or intravenous catheter 
line infections intermittent courses are used rather than prolonged treatment.384,385 There 
is a single paper published from South and East Asia regarding the use of decolonisation 
to prevent infections in peritoneal dialysis patients in India.376 Gastrointestinal tract MRSA 
colonisation can represent a significant reservoir of MRSA since it can result in 
widespread environmental contamination.456 Gastrointestinal decolonisation with oral 
vancomycin has been successfully used to reduce MRSA transmission 457
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1.3.5 “Search and destroy” policy
The prevalence of MRSA across Europe varies almost 100-fold, between the lowest rates 
seen in the Netherlands and Scandinavia (0.6-1%) and the highest rates in the UK 
(41.5%) and Greece (44.4%)458 These low rates of MRSA in the Netherlands and 
Scandinavia are attributed to their adoption of a “search and destroy” policy towards 
MRSA.459,460 This policy consists of actively screening for MRSA colonisation amongst 
patients and healthcare workers, isolation of colonised or infected patients to a single 
room with one allocated nurse, decolonisation of patients and healthcare workers until 
screening swabs are negative, healthcare workers are suspended from work until they are 
proven to no longer to carry MRSA, patients remain isolated until their screening swabs 
are negative, screening of the contacts of an index infected case and ward closure if more 
than 1 patient is infected or colonised on that ward 461,462 If a “search and destroy” policy is 
implemented in a hospital with endemic MRSA then it can take up to 6 years for the 
prevalence of MRSA to fall below 1%.459 A “search and destroy” policy is expensive to 
implement459,461,462 and therefore unlikely to be cost-effective for developing countries.
1.3.6 Antibiotic stewardship
Excessive and/ or inappropriate antibiotic use drives the emergence of drug-resistant
strains.406 Work on the evolution of S. aureus clones has demonstrated that MSSA strains
that are well adapted to transmission within hospitals repeatedly receive the mec
determinant following the use of methicillin and related antibiotics,170 which condones a
survival advantage in the healthcare environment. Fluoroquinolones 463,464
cephalosporins465,466 and beta-lactamase penicillin antibiotics466 have all been associated
with acquisition of MRSA. For this reason, antibiotic stewardship is an important
component of MRSA infection control. This involves educating prescribers, instituting and
auditing adherence to an antibiotic policy; preventing under-dosage of antibiotics and
ensuring correct duration of antibiotic courses; consideration of antibiotic cycling; and
reducing broad-spectrum antibiotics as much as possible, especially following culture
results 406,467 Programmes focussing on antibiotic stewardship in developed countries
24
have significantly reduced rates of MRSA infection and colonisation.468,469 There is limited 
data on antibiotic stewardship from South and East Asia, although it is recognised as an 
important strategy 470 Antibiotic stewardship was one of a number of interventions involved 
in reducing nosocomial infection rates from a study in a special care nursery in 
Bangladesh.448 Antibiotic overuse has been recognised as a problem in China471 and 
Nepal.67,472,473 In addition, sub-standard antibiotic drugs are rife across resource-restricted 
countries in South and East Asia198 and these are likely to help drive drug resistance rates 
higher given the reduced amount of active drug present.
1.3.7 World Health Organisation challenge
The World Health Organisation launched the first of their Global Patient Safety Challenges 
in October 2005 with the slogan “Clean care is safer care”.474 The campaign focuses on 
reducing healthcare-associated infections. The aim of the challenge is to promote safe 
hand hygiene practices globally and at all levels of healthcare as a first step in ensuring 
high standards of infection control and patient safety. It included producing guidelines on 
hand hygiene for use globally. The resource-restricted countries from South and East Asia 
which have signed up to the challenge are Bangladesh, Maldives, Mongolia, Thailand and 
Vietnam.
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1.4 Aims of this thesis
Overall, the work described in this thesis was aspiring to raise the profile of S. aureus 
disease as an important pathogen in developing countries, using Thailand as an example 
of a resource-restricted country from South and East Asia. More specifically my aims were 
to:
1. Define the epidemiology of S. aureus disease in the tropics.
2. Determine the clinical manifestations of S. aureus disease in the tropics.
3. Ascertain the rate of MRSA infection, the antibiotic sensitivity profiles and 
presence of community-acquired MRSA in a resource-restricted country.
4. Elucidate the impact of MRSA on antibiotic prescribing and its efficacy.
5. Define the S .aureus-attributable mortality rate and the factors that predict mortality 
in a resource-restricted country.
6. Establish whether implementation of the “Surviving Sepsis Campaign” guidelines 
would be feasible in a resource-restricted setting.
7. Determine the prevalence of Panton-Valentine Leukocidin amongst S. aureus 
isolates causing disease in an unselected population.
8. Define rates of MRSA carriage amongst patients and nursing staff of Intensive 
Care Units and likely modes of transmission.
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Chapter 2. Methods and materials
2.1 Retrospective clinical study
2.1.1 Participants and clinical methods
Ethical approval was obtained from the Ethical Committee of the Faculty of Tropical 
Medicine, Mahidol University, Thailand and the Oxford Tropical Research Ethics 
Committee. A retrospective, observational study of S. aureus bacteraemia was performed 
at Sappasithiprasong Hospital in northeast Thailand, which lies 70 km west of Lao PDR 
and 95 km north of Cambodia. This hospital serves the province of Ubon Ratchathani with 
a catchment of 2 million people, providing both primary care to the town inhabitants and 
tertiary care to the inhabitants of the province. It is a 1,100-bed hospital with 
comprehensive clinical and laboratory services.
The computerised records of the hospital diagnostic microbiology laboratory were 
interrogated to identify all patients with S. aureus grown from a blood culture between 1st 
June 2003 and 31st December 2004. In-patients of all ages with a pure growth of S. 
aureus were eligible for inclusion. Clinical paper notes were available from the hospital 
medical records department on 135 out of 157 patients (86%), with limited data available 
from hospital computer records for the remaining 22 cases. The paper notes were used to 
collect information on patient characteristics, past medical history, presenting symptoms 
and examination, cultures taken and results, investigation results, sites of infection, 
antibiotic treatment and other management, and outcome. The data available on the 
computerised records were culture details including ward of collection, admission and 
discharge dates, date of birth, sex, dates of subsequent hospital attendance and death. 
Additional out-of-hospital deaths were established from checking the National Death 
Register. Data were recorded on standardised forms adapted from those used by Fowler 
et al161 (Appendix 1). Final outcome was determined 12 weeks from the date of the first 
positive blood culture result for S. aureus, in keeping with the Fowler et al study.161
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2.1.2 Definitions
Community-acquired infection was defined as a positive S. aureus blood culture taken 
within 2 days of admission to hospital. Nosocomial infection was defined as a positive S. 
aureus blood culture taken more than 2 days after admission.
2.2 Prospective clinical study
2.2.1 Participants and clinical methods
Ethical approval was obtained from the Ethical and Scientific Review sub-committee of the 
Royal Thai Government Ministry of Public Health and the Oxford Tropical Research Ethics 
Committee. A prospective, observational study of invasive S. aureus disease was 
conducted at Sappasithiprasong Hospital in northeast Thailand over a 1 year period from 
November 2006 to November 2007. Potential study patients were identified by daily 
consultation with the hospital diagnostic microbiology laboratory. Patients of all ages with 
at least one clinically significant culture sample taken from a normally sterile site positive 
for a pure growth of S. aureus were considered for inclusion. Blood culture was 
considered to represent a sterile site sample, and other sample types were determined 
based on details in the clinical notes and discussion with hospital staff. Surface swabs and 
other samples that were not collected from usually sterile sites or not obtained via 
aspiration or an operative procedure were excluded. Patients were enrolled into the study 
after written informed consent was obtained, and were visited daily by study investigators 
until discharge to record progress and management.
More detailed information could be collected compared with the retrospective 
study since the patient and/or relatives were interviewed, the patient examined by the 
study investigators, and hospital staff (especially the ward nurses) were able to elaborate 
on management plans which were usually scantily documented. Data were recorded on 
standardised forms adapted from those used by Fowler et al161 and further modified from 
the retrospective study to accommodate the greater detail (Appendix 2). Additional data 
was collected on the severity of illness and sepsis management for the 3 day period
28
starting from the day the first culture positive for S. aureus was taken, a time frame 
chosen to reflect the 72 hours of early goal-directed therapy for sepsis described by 
Rivers et al312 (Appendix 3). The aspects of sepsis management evaluated were those 
detailed in the ‘Surviving Sepsis Campaign’ guidelines published in 2004.339 However, 
these guidelines were revised and published before the analysis of these data and hence 
were assessed against the 2008 updated guidelines.340 Clinical care was provided by the 
hospital physicians, independent of the research team. Sites of S. aureus infection were 
established based on examination findings and referral to the medical notes, including 
investigation reports and operation notes. Final outcome was determined 12 weeks from 
the date the first culture positive for S. aureus was taken, in keeping with the Fowler et al 
study,161 using a standardised telephone questionnaire.
The study-specific investigations performed were a repeat blood culture taken 48- 
96 hours after the first culture positive for S. aureus was taken and a transthoracic 
echocardiogram. Results of these study investigations were given to hospital physicians 
caring for the patient. Echocardiograms on patients aged less than 14 years were 
performed by the hospital paediatric echocardiographer, while echocardiograms on the 
remainder were performed by a study investigator and reviewed or repeated as 
appropriate by the hospital cardiologist. Subsequently the echocardiograms carried out by 
the study investigator were reviewed by a cardiologist in Oxford.
2.2.2 Definitions
Community-acquired infection was defined as a positive S. aureus sterile site culture and 
admission to hospital with an illness consistent with invasive S. aureus disease. 
Nosocomial infection was defined as a positive S. aureus sterile site culture taken more 
than 48 hours after admission for another condition. Non-nosocomial healthcare- 
associated infection was defined as community-acquired infection in an individual who 
had contact with healthcare services in the preceding year, using the criteria described by 
Fowler et al.161 Outcomes at 12 weeks were defined as: (i) cure - clinically improved and 
no additional sites of infection present or suspected; (ii) unresolved infection - persistent
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features of infection with or without persistent positive cultures; (iii) death attributable to S. 
aureus - when death was due to S. aureus infection in a previously healthy individual or 
when S. aureus hastened death in the presence of an underlying condition such as 
cancer; or (iv) death due to other causes - in which the S. aureus infection did not appear 
to contribute to death.
2.3 Laboratory methods for the clinical disease studies
2.3.1 Hospital diagnostic microbiology laboratory
The hospital diagnostic microbiology laboratory processed all samples using routine 
procedures, including antibiotic susceptibility testing using the disk diffusion method.475 
Susceptibilities reported to hospital physicians were penicillin, oxacillin, cefazolin, 
erythromycin, clindamycin and trimethoprim-sulphamethoxazole for methicillin-susceptible
S. aureus (MSSA). Methicillin-resistant S. aureus (MRSA) were additionally tested for 
vancomycin and fusidic acid. For the retrospective study, isolates were determined as 
MRSA based on the oxacillin disk diffusion assay.
2.3.2 Antibiotic susceptibility testing in research laboratory
In the prospective study, a total of 248 out of 270 S. aureus isolates (first positive sample 
for each patient, with preference given to blood culture samples when two different 
samples taken on the same day were both positive) were available and obtained for 
further testing, re-identified and stored at -80°C. Species verification was ascertained 
using coagulase and latex agglutination (Staphaurex Plus) tests. Isolates were evaluated 
against an extended antibiotic panel of cefoxitin, chloramphenicol, ciprofloxacin, 
clindamycin, erythromycin, fusidic acid, gentamicin, mupirocin, netilmicin, penicillin, 
rifampicin, trimethoprim-sulphamethoxazole, tetracycline and vancomycin using the disk 
diffusion method 475 Isolates that were resistant to cefoxitin by disk diffusion were further 
evaluated by oxacillin and vancomycin E-tests (AB Biodisk). Isolates from the prospective 
study were designated as MRSA based on the oxacillin E-test for the 248 isolates re­
tested in the research laboratory, and based on the oxacillin disk diffusion assay for the 22
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isolates that were tested by the hospital laboratory and were not available for further 
testing.
2.3.3 Polymerase chain reaction (PCR) in research laboratory
A multiplex polymerase chain reaction (PCR) was used to determine the presence of 
mecA, the genes encoding Panton-Valentine Leukocidin (PVL) and the 16S rRNA gene 
(internal positive control). A 1ml overnight culture of S. aureus with an optical density of
1.0 at 600nm was centrifuged at 16,000xg for 30 seconds and the cell pellet re­
suspended with 200|iL phosphate buffer solution (pH 7). Genomic DNA was extracted 
using the High Pure PCR Template Preparation Kit (Roche Applied Science, Germany), 
with an additional step of incubation at 37°C for 30 minutes with 0.5pL of 10mg/ml 
lysostaphin solution (Sigma, USA) prior to cell lysis. The primers used were as described 
previously for mA1 and mA2 (mecA),476 luk-PV-1 and luk-PV-2 (PVL),266 and Staph756F 
and Staph750R (Staphylococcus genus-specific 16S rRNA gene) 477 A 25pL PCR reaction 
was used containing 10-120ng genomic DNA, 5pmol of each primer (Proligo Singapore 
Pty Ltd), 200pM dNTP (Qiagen, Germany), 1.25 units of Taq polymerase (Roche Applied 
Science, Germany), 4.5mM MgCI2 and Ixbuffer. PCR was performed using a PTC-200 
Peltier Thermal Cycler (MJ research, USA). The PCR conditions were one cycle of 95°C 
for two minutes, 30 cycles of 15 seconds at 95°C, 15 seconds at 56°C; 45 seconds at 
72°C, and a final step of 72°C for seven minutes. Amplification product size was 
determined by reference to a 100-bp molecular weight marker (Biolabs New England, UK) 
using 2% agarose gel electrophoresis.
2.4 MRSA carriage study
2.4.1 Participants and clinical methods
Ethical approval was obtained from the Ethical and Scientific Review sub-committee of the
Royal Thai Government Ministry of Public Health and the Oxford Tropical Research Ethics
Committee. A prospective, observational study of MRSA carriage and transmission was
conducted in 2 Intensive Care Unit (ICU) wards at Sappasithiprasong Hospital in
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northeast Thailand for a period of 3 months, from 1st March 2008 to 31st May 2008. The 
study ICU wards were a general paediatric ICU, which contained 7 beds and 7 cots in 
open plan, and an adult surgical ICU that had 8 beds in open plan. These wards were 
chosen as they had harboured patients with MRSA bacteraemia in the previous 
prospective clinical study. All patients admitted to the study ICU wards were eligible for 
inclusion and patients were enrolled into the study after providing written informed 
consent. Data was recorded for each patient with particular emphasis on ward locations 
prior to the study ICU, antibiotic treatment and development of any nosocomial infection 
(Appendix 4).
Screening swabs of the anterior nares, throat, axillae and wounds if present, were 
taken using pre-moistened sterile cotton-tipped swabs on admission (or within 24 hours of 
admission), then twice weekly during the length of their stay on the study ward and on 
discharge from this ward. At the same time points those patients who were catheterised 
had a 1ml sample of urine aspirated from their catheter tubing and those patients who 
were intubated had a tracheal suction sample taken instead of a throat swab.
The nursing staff working on the study ICU wards were eligible for inclusion and 
were enrolled into the study after providing written informed consent. Basic demographic 
information, including their nursing grade and number of years working, was recorded. 
Nursing staff had screening nasal swabs and finger tip cultures at 3 unannounced time 
points over the study period. The finger tip cultures were obtained by the direct placement 
of the fingertips of the nurse’s dominant hand onto a Columbia blood agar plate.429 Covert 
surveys of hand washing were performed every 2 weeks throughout the study on each 
study ICU ward using the Hand Hygiene Observation Tool 478
2.4.2 Laboratory methods
After swabbing the end of the swab was broken off into a bijou with 1 ml of sterile 
phosphate buffer solution (PBS). After returning to the laboratory (and within two hours of 
sampling), the bijou were vortexed and then 100pL (10pL only for nasal swabs) of swab 
fluid was spread inoculated onto a phenol red mannitol salt agar plate and the remainder
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of the fluid, including the swab tip was added to 7ml phenol red mannitol salt agar broth. 
The agar plates were incubated for 48 hours and the broth for 7 days at 37°C in air. If no 
colonies were identified on the agar plate then the broth was checked for a change in 
colour from red to yellow at 48 hours and 7 days, which if observed then 10pL broth was 
plated to phenol red mannitol salt agar. Suspected colonies on agar were verified using 
coagulase and latex agglutination tests. The finger imprint Columbia blood agar plates 
were incubated for 48 hours at 37°C in air and suspected colonies processed as with the 
swab plates. Methicillin susceptibility was tested using a cefoxitin disk on Mueller-Hinton 
agar.
On return to the laboratory (within 2 hours of sampling), the section of tubing from 
tracheal suction sampling in its universal container was vortexed to obtain the sputum, 
after which the tubing was discarded. 1ml sterile PBS was added to the sputum and 
vortexed then the sample was processed in the same manner as the swab samples. The 
1ml urine samples collected by syringe from the catheter tubing were placed into a bijou 
and on return to the laboratory 10pL was spread inoculated neat onto the phenol red 
mannitol salt agar plate and cultured for 48 hours at 37°C in air. The remaining urine was 
spun to obtain a pellet and the pellet added to the phenol red mannitol salt agar broth, 
which was incubated for 7 days at 37°C in air. Then the urine samples were processed in 
the same manner as the swab samples.
Isolates were stored at -80°C and subsequently an extended antibiotic 
susceptibility profile was determined using the disk diffusion method475 for 
chloramphenicol, ciprofloxacin, clindamycin, erythromycin, fusidic acid, gentamicin, 
mupirocin, netilmicin, penicillin, rifampicin, trimethoprim-sulphamethoxazole, tetracycline 
and vancomycin. Isolates that were resistant to cefoxitin by disk diffusion were evaluated 
by oxacillin E-tests (AB Biodisk). The first MRSA isolate for each patient additionally 
underwent multiplex PCR for mecA, 16S ribosomal RNA (internal control) and the gene 
encoding PVL, as described above in section 2.3.3.
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2.4.3 Results confidentiality
The results of cultures grown from the swabs of patients as part of the study were kept 
confidential since the swabbing of patients to look for MRSA colonisation is not routine 
practice on either of the study wards and isolation of infected or colonised patients is not 
possible. Additionally, all the results of cultures grown from nursing staff were kept 
confidential.
2.5 Statistical analysis
2.5.1 Retrospective clinical study
Data was entered into Excel spreadsheets. Data analyses were performed using Stata 
software version 9 (StataCorp, College Station, Texas). Fisher’s exact test was employed 
to compare categorical data. Continuous data was compared with Student’s t test 
because the standard deviations were similar, even though the data was not normally 
distributed.
2.5.2 Prospective clinical study
Data was double entered into a FileMaker Pro database (version 7). Data analyses were 
performed using Stata software version 9 (StataCorp, College Station, Texas). Categorical 
data were compared using Fisher’s exact test. Student’s t test was used for continuous 
data when the data was normally distributed or the standard deviations were similar; 
otherwise the Mann-Whitney U test was employed. Kaplan-Meier survival curves were 
plotted for attributable and non-attributable deaths, and for S. aureus-attributable deaths 
in children and adults (non-attributable deaths censored). These survival curves were 
compared using the log rank test. In order to determine the risk factors for mortality, 
variables significant at p<0.20 on univariable analysis and with 5 or more events (deaths) 
were used in the multivariable logistic regression model. Superficial and deep abscesses 
were combined so that there were 5 events. Prematurity was excluded given the low 
number of cases overall (n=7). Variables which did not reach this threshold were reviewed
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and those considered a priori to potentially have an important influence on outcome were 
added (diabetes mellitus was the only variable in this category). Stepwise removal and 
addition of variables were used to determine the final multivariable model (p for removal 
0.1 and p for re-entry 0.05). Missing PVL data was excluded from the multivariable logistic 
regression. Potential interactions were assessed using logistic regression. Reported p 
values are two-tailed.
2.5.3 MRSA carriage study
Data was entered into Access databases. Data analyses were performed using Stata 
software version 9 (StataCorp, College Station, Texas). Categorical data were compared 
using Fisher’s exact test. Student’s t test was used for continuous data with a normal 
distribution; otherwise the Mann-Whitney U test was employed.
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Chapter 3. Retrospective study of S. aureus bacteraemia in a tropical setting
3.1 Chapter content
Invasive S. aureus disease is poorly understood in tropical settings. A study specifically 
evaluating S. aureus bacteraemia, rather than all-cause bacteraemia, had not been 
reported in the English language literature from resource-restricted South or East Asia 
prior to the work for this thesis. This retrospective observational study of S. aureus 
bacteraemia was performed to assess the burden of morbidity and mortality in a resource- 
restricted tropical setting. In addition, the data generated formed the basis for the 
development of hypotheses and informed the design of a subsequent prospective study of 
invasive S. aureus disease described in Chapters 4-6. Study methods were described in 
Chapter 2.
3.2 Results
The quality of the documentation in the hospital patient notes was low. The handwriting 
was sometimes illegible and some patients had no record of history and/or examination 
findings. Amongst the scanty progress notes, there was no documentation provided to 
explain antibiotic choice or change of treatment in any of the cases. For 135 of the 157 
cases identified, there were hospital paper patient records available and for the remaining 
22 cases basic data was obtained from the hospital electronic records.
3.2.1 Patient characteristics
Over the 19 month period considered for the study, there were 157 cases of S. aureus 
bacteraemia identified from the hospital diagnostic microbiology laboratory electronic 
database. The age range of patients on the day their culture was taken was from 1 day of 
life to 94 years (median 33 years, interquartile (IQR) range 1 to 59 years). The largest age 
group was patients aged less than 1 year (25%); the age distribution of the study patients 
is shown in decade blocks in Figure 3.1. Of the 39 patients aged less than 1 year, 27 
(69%) were neonates (aged less than 1 month) at the time of their culture. There was a
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significant predominance of males (n=98, 62%, p=0.002). Amongst the 135 patients with 
paper records, a chronic underlying illness was detailed in the notes of 47 patients (35%) 
although 17 patients (13%) had no documentation relating to past medical history. The 
most common underlying diseases recorded were diabetes mellitus (n=19) and chronic 
renal failure (n=15). The median length of stay for all patients was 9 days (IQR 5 to 19 
days), with 32 patients (20%) admitted for 3 days or less. The cases of S. aureus 
bacteraemia occurred throughout the hospital.
3.2.2 Types of infection
For nearly half the patients with paper records, it was not possible to identify a site of 
infection beyond bacteraemia (n=66; 49%). However, amongst the cases where it was 
possible a broad spectrum of sites of infection was seen including invasive disease such 
as pneumonia, septic arthritis, pyomyositis and endocarditis as well as more superficial 
infections like those affecting the skin and soft tissue (Table 3.1). A total of 72 sites of 
infection were found from 69 patients; 3 patients each had 2 identified sites. The most 
common sites were skin and soft tissue infection (21 sites, 29% of all sites) and 
pneumonia (17 cases, 24%). Although there were 13 patients with infection related to 
prosthetic material and/ or surgery, in a further 9 cases there was prosthetic material 
present or there had been a preceding operation but the documentation was not sufficient 
to determine whether the bacteraemia arose as a result of these.
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Table 3.1: Sites of infection
Site of infection Number of sites (n=72)
(% of total sites)
Skin and soft tissue infection 21 (29%)
Pneumonia*1 17 (24%)
Infection related to prosthetic material and/ 
or surgery*2
13(18%)
Septic arthritis 7(10%)
Pyomyositis 5 (7%)
Urinary tract infection 4 (6%)
Other infections*3 3 (4%)
Endocarditis 2 (3%)
*12 cases of pneumonia also had empyema
*2 Infection related to prosthetic material and/ or surgery includes: central intravenous 
catheter (n=4), haemodialysis graft (n=2), umbilical vein catheter (n=1), pacemaker (n=1), 
post metallic mitral valve replacement (n=1), following closure of 7mm atrial septal defect 
(ASD) (n=1), after pericardiectomy and insertion of mediastinal drain (n=1), post above 
knee amputation (n=1) and following orthopaedic operation and insertion of metalwork (n 
= 1).
*3 Other infections category includes: liver abscess (n=1), central nervous system infection 
(n=1) and sepsis following an out-of-hospital abortion (n=1).
38
The number of investigations recorded in the paper notes was low. A transthoracic 
echocardiogram was performed on 13 patients, although the reports from 8 of these did 
not mention vegetations or endocarditis. There were 2 patients with metallic heart valves 
and S. aureus bacteraemia, neither of whom had a transthoracic echocardiogram 
performed. A documented search for possible collections of pus or other sites of infection 
was recorded in the notes of a single patient. From the 135 patients with paper records 
available, 44 patients (33%) had a repeat blood culture taken (after the day the first 
culture positive for S. aureus was taken), from which 7 (16%) were positive for S. aureus.
3.2.3 Drug resistance
The rate of MRSA infection was 23% of all cases (n=36). There were 48 cases of hospital- 
acquired infection, of which 28 (58%) were caused by MRSA. There were 8 “community- 
acquired” cases of MRSA, but all of these patients had attended Sappasithiprasong 
Hospital in the preceding year, with 7 having been in-patients.
3.2.4 Antibiotic treatment
The median duration of in-patient antibiotic treatment was 8 days (IQR 4-17 days) 
amongst the 135 patients with paper notes. The choice of antibiotics prescribed was 
highly variable and poly-pharmacy was commonplace. Considering cloxacillin and 
vancomycin as the gold standard treatment for MSSA and MRSA bacteraemia 
respectively, 53 patients (44%; 19 (16%) unknown treatment) infected with MSSA and 16 
patients (44%; 3 (8%) unknown treatment) infected with MRSA received the gold standard 
choice of antibiotic for their bacteraemia. Amongst the 16 patients treated with 
vancomycin, 3 received their first dose of vancomycin on the day the positive culture was 
taken, whilst the median delay was 5 days (IQR 3-6 days) for the remaining 13 patients. 
Given the wide variety of antibiotics prescribed and the limited antibiotic susceptibility 
profile reported by the hospital diagnostic microbiology laboratory, it was not possible to 
accurately determine the proportion of patients who received effective antibiotic therapy 
for their S. aureus bacteraemia and time delays to effective treatment for MSSA patients.
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3.2.5 Procedures for infectious source control
Procedures for infectious source control were recorded on 8 patients (6% of those with 
paper records). The procedures were: joint washout (n=3), debridement (n=3), incision 
and drainage (n=1) and revision of pacemaker (n=1).
3.2.6 Mortality
The overall mortality rate at 12 weeks was 48%. Age-specific mortality is shown in Figure 
3.1. There was a highly significant association between increasing age and mortality 
(p=0.001). Amongst those patients with paper medical records and documented details on 
the presence or absence of chronic underlying diseases (n=118), there was a significant 
association between the documented presence of chronic underlying diseases and death; 
mortality rates were 60% and 39% for presence and absence, respectively (p=0.039). The 
mortality rate for infection with MRSA was significantly higher than for MSSA, 67% versus 
43%, respectively (p=0.014). Amongst the patients with paper medical records (n=135), 
there was a trend towards a reduced mortality if a site of infection in addition to 
bacteraemia was identified; mortality was 42% in those with an identified site of infection 
compared with 58% in those without (p=0.086).
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Figure 3.1: Age distribution and age-specific mortality rates and disease burden for 
157 cases of S. aureus bacteraemia.
The burden of S. aureus bacteraemia is highest amongst the youngest age group
(<1 year) whilst overall mortality increased significantly with age (p=0.001), analysing age
as a continuous variable.
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3.3 Discussion
This retrospective study has demonstrated that S. aureus bacteraemia is an important 
cause of morbidity and mortality in the resource-restricted tropical setting of the study 
hospital. Over the study period S. aureus accounted for 9% of positive blood cultures, the 
third most common cause after Escherichia coli (17%), and Burkholderia pseudomallei 
(the cause of melioidosis) (14%). The overall mortality was double that found in studies 
from the USA (28% mortality in one large study;161 30% in those aged over 65, and 15% 
overall in adults aged 18-60 years in a second study).479 The mortality rate is similar to 
death rates following bacteraemic melioidosis, which is the other major cause of 
bacteraemia and sepsis-related death in Ubon Ratchathani.480,481 Follow-up data after 
discharge from hospital was limited as a result of the retrospective study design and was 
only available if the patient returned to Sappasithiprasong Hospital either as an in-patient 
or an out-patient. National death registry information was used to more accurately verify 
the mortality rate. Therefore the data available does not support the ascertainment of an 
accurate attributable mortality rate.
Mortality increased significantly with age and the presence of chronic underlying 
diseases, which would also be expected to increase with age. Given the limited data on 
chronic underlying diseases, reducing the number of cases in logistic regression from 157 
to 115, the effect of potential confounding between age and chronic underlying diseases 
could not be accurately determined. More complete data on chronic underlying diseases 
would facilitate the investigation of the significance of this potential confounding effect.
MRSA was a significant problem in the study hospital, and the death rate of 
patients infected with MRSA was extremely high, significantly more than for MSSA. Less 
than half the patients received gold standard antibiotic therapy for their bacteraemia but 
given the wide variety of antibiotics used and the limited antibiotic susceptibility profiles 
available it was not possible to accurately establish the proportion of patients receiving 
effective antibiotic therapy, either empirically or following culture results. Delays in 
effective antibiotic therapy for S. aureus bacteraemia are known to adversely affect 
outcome186 and the delays in receiving vancomycin for the majority of patients infected
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with MRSA may have contributed to the higher mortality rate for MRSA. Although the 
median duration of antibiotic treatment appears shorter than that usually recommended 
for bacteraemia, because of the retrospective design it was only possible to record the 
antibiotic course received in the study hospital. Therefore meaningful conclusions over 
antibiotic treatment duration and its relationship to outcome were not possible. It was only 
practical to base the differentiation of community-acquired infection versus hospital- 
acquired infection on the timing of cultures compared with admission. This does not take 
account of possible healthcare-associated infection arising whilst the patient is not 
admitted to hospital and can be an important source of MRSA.
The broad range of sites of infection recorded is in contrast to the textbook156'158 
focus on pyomyositis as the ‘tropical’ form of S .aureus disease. Of note in this study there 
were just 5 cases of pyomyositis seen. However, the comparatively low rate of identified 
sites of infection beyond bacteraemia is not consistent with the very high death rate and 
indicates that these may be under-recognised and under-investigated. For example, there 
were no cases of osteomyelitis, and only one solid organ abscess and 2 cases of 
endocarditis. From this retrospective study it was not feasible to distinguish whether 
investigations were carried out and not recorded, or were not performed. On a similar 
note, there was a very low rate of procedures for infectious source control.
There are inherent limitations of a retrospective study and these were further 
exacerbated by the lack of and poor quality documentation of hospital paper records and 
no access to the infecting isolates. Nevertheless, the study provided useful data to inform 
the design of a future prospective study. It was clearly going to be essential to be able to 
interview the patients and their relatives to obtain fuller details on the presentation of the 
infection, underlying chronic medical conditions and previous healthcare contact, as well 
as being able to examine the patient. The ability to contact the patient by phone or letter to 
accurately establish follow-up data, further antibiotic treatment and outcome would be 
invaluable. Discussions with hospital staff about management in addition to referral to the 
medical notes, and having radiological images available on the ward, would also be 
expected to enhance the quality of the data considerably. In addition, in a prospective
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study it would be achievable to include all culture samples from usually sterile sites 
because the source of the sample could be ascertained from the hospital staff or patient if 
the notes were not sufficiently detailed. This would be predicted to give a more accurate 
picture of the manifestations of invasive S. aureus disease in a tropical setting, rather than 
just focussing on bacteraemic patients. Furthermore, the infecting isolates would be saved 
and evaluated further in the research laboratory in order to determine a more detailed 
antibiotic susceptibility profile, and molecular techniques undertaken to define the 
presence of the mecA gene for MRSA confirmation and the presence of the putative 
virulence determinant Panton-Valentine Leukocidin. Information would also be collected 
on occupation, as it could be a possible explanation for the significantly higher number of 
males seen in this study.
Hypotheses developed as to possible causes for the high mortality rate found were 
lack of investigations to identify sites of infection and pus collections, lack of procedures 
for infectious source control and inappropriate antibiotic prescribing. Specific 
investigations to be introduced in the prospective study were a transthoracic 
echocardiogram for every patient with bacteraemia since endocarditis can complicate S. 
aureus bacteraemia and has a high mortality rate,482 and a repeat blood culture taken 48- 
96 hours after the first culture positive for S. aureus since this has been shown to be the 
most effective predictor of complications following S. aureus bacteraemia in a US based 
study carried out by Vance Fowler et al.161
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Chapter 4: Prospective study of risk factors for death and interventions to reduce 
mortality
4.1 Chapter content
The retrospective study of S. aureus bacteraemia, described in Chapter 3, established 
that S. aureus was responsible for considerable morbidity and mortality in a resource- 
restricted tropical setting. However, there were limitations to the data due to the 
retrospective nature of the study. The design of this prospective observational study of 
invasive S. aureus disease was informed by the retrospective study and devised to 
undertake a more detailed assessment of the risk factors for mortality and interventions to 
reduce mortality. This prospective study was carried out in the same study hospital in 
northeast Thailand. Study methods were described in Chapter 2.
4.2 Results
4.2.1 Recruitment
Over the 1 year study period a total of 295 patients were identified with at least one 
clinically significant culture from a normally sterile site positive for a pure growth of S. 
aureus. Of these, 270 patients were recruited and 25 patients could not be studied either 
because they declined consent (n=21) or because they had left the hospital by the time 
the culture became positive and could not be contacted (n=4).
4.2.2 Culture samples
From the 270 study patients there were 335 sterile site cultures positive for S. aureus, of 
which 201 were pus specimens obtained by aspiration or from operative procedures, 125 
were blood cultures, 5 were pleural fluid, 3 were cerebrospinal fluid (CSF), and one was 
peritoneal dialysate. Considering patients as the denominator, 100 patients (37%) had 
positive blood cultures of whom 14 had at least one other positive sterile site culture from 
an identified focus of infection, and 170 patients had positive pus culture(s) alone.
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4.2.3 Outcome
The all-cause mortality rate at 12 weeks was 26% (70/270), of which 20% (55/270) were 
attributable to S. aureus infection. Overall mortality for bacteraemic patients was 53%, 
compared with 10% in patients without a positive blood culture (p<0.001). Mortality rates 
were 16% (14/87) for children and 31% (56/183) for adults (p=0.01), of which 14% and 
25% were attributable to S. aureus, respectively. The majority of infections (191, 71%) 
were community-acquired, of whom 34 (18%) died (Table 4.1). The remainder comprised 
27 (10%) cases of non-nosocomial healthcare-associated infection of whom 9 (33%) died, 
and 52 (19%) cases of nosocomial infection of whom 27 (52%) died (p<0.001 for 
comparison of 3 groups). Most of the 200 patients who survived to follow up at 12 weeks 
were cured (n=189). The remaining 11 patients had a range of unresolved S. aureus 
infections: empyema (n=2), diabetic foot infection (n=2), infected orthopaedic material 
(n=2), infected pacemaker with endocarditis (n=1), osteomyelitis plus pyomyositis with 
(n=1) or without (n=1) septic arthritis, septic arthritis alone (n=1) or orbital abscess (n=1).
4.2.4 Patient characteristics
The patient characteristics are summarised in Table 4.1. Age on the day the first culture 
positive for S. aureus was taken ranged from 1 day to 92 years (median 39 years). Overall 
and attributable mortality were significantly associated with increasing age (p<0.001 for 
both), and overall mortality but not attributable mortality was associated with prematurity 
(p=0.014). The majority of patients (98%) were Thai and the remaining 5 patients were 
from neighbouring Lao PDR. Three quarters of patients over the age of 16 years were 
manual labourers (a reflection of the major form of employment for people living in this 
region), but this group were not at increased risk of death. Almost half of patients (49%) 
had one or more of the underlying medical conditions that were recorded during the study, 
of which diabetes mellitus was the most frequent. The presence of pre-existing cardiac, 
renal or lung disease was significantly associated with all-cause mortality and pre-existing 
cardiac and renal disease were significantly associated with attributable mortality.
However no association was found between death and either diabetes mellitus or
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immunosuppression. The positive association between increasing age and mortality 
remained significant when adjusted for all underlying co-morbidities (p=0.01), pre-existing 
cardiac (p=0.001), renal (p=0.001) or lung disease (p<0.001).
4.2.5 Clinical manifestations
The majority of the 270 patients (n=231, 86%) had one or more identifiable extra-vascular 
sites of infection, while no site of infection was identified other than positive blood culture 
in the remaining 39 cases (Table 4.2). Superficial and deep abscesses accounted for the 
majority of infections (34% and 17%, respectively). A wide range of other clinical 
presentations were represented, including bone and joint infection, respiratory infection, 
endocarditis and nosocomial infections including post-operative wound infection and 
infections related to the presence of prosthetic material. Superficial and deep abscesses 
were strongly associated with a survival benefit (p<0.001 and p=0.004, respectively), 
while respiratory infections and having a blood culture positive for S. aureus were strongly 
associated with all-cause and attributable death (p<0.001 for all comparisons). Patients 
with an identified extra-vascular site of infection were less likely to die than those patients 
with bacteraemia alone (all-cause 20% vs. 59%, p<0.001; attributable 16% vs. 56%, 
p<0.001).
47
Ta
ble
 
4.1
: 
As
so
ci
at
io
n 
be
tw
ee
n 
pa
tie
nt
 c
ha
ra
ct
er
is
tic
s 
an
d 
ou
tc
om
e 
for
 2
70
 
pa
tie
nt
s 
wi
th 
in
va
siv
e 
S. 
au
re
us
 
in
fe
ct
io
n
At
tri
bu
ta
bl
e 
p 
va
lu
e*
2
<
0
.0
0
1
0.
87
8
>0
.9
99
0.
39
6
0.
15
2 o
o
o
V 0
.5
36
0.
34
5
©
o <
0
.0
0
1
0.
74
8 o
o
o
V 0
.0
0
1
<
0
.0
0
1
<
0
.0
0
1
S. 
au
re
us
-a
ttr
ib
ut
ab
le
 
de
at
hs
 
(n
=5
5)
Nu
m
be
r, 
% 
of
 
at
tri
bu
ta
bl
e 
de
at
hs
56 
(3
0-
68
)
34 
(6
2%
)
34 
(7
7%
) 
(n
=4
4)
21 
(4
8%
) 
(n
=4
4)
3 
(5
%
)
39 
(7
1%
)
10
(1
8%
)
8(
15
%
)
10
(1
8%
)
15 
(2
7%
)
4 
(7
%
)
25 
(4
5%
)
7(
13
%
) Co
0 s
CM
CO
CM 17
(3
1%
) Co
CM
CO
CO 13
(2
4%
)
Al
l-c
au
se
 
p 
va
lu
e*
1
<
0
.0
0
1
>0
.9
99
0.
45
9
>0
.9
99
0.
01
4
<
0
.0
0
1
>0
.9
99
0.
37
7
0.
00
3
<
0
.0
0
1 9C
00
o
o
d
V
o
o
o
V <
0
.0
0
1
<
0
.0
0
1
Al
l-c
au
se
 
de
at
hs
 
(n
=7
0)
Nu
m
be
r, 
% 
of
 
all
 d
ea
th
s
55 
(3
2-
70
)
42 
(6
0%
)
46 
(8
1%
) 
(n
=5
7)
II
o S
CO
5 
(7
%
)
50 
(7
1%
)
11 
(1
6%
)
10
(1
4%
)
13
(1
9%
)
19 
(2
7%
)
8(
11
%
)
34 
(4
9%
)
9(
13
%
)
27 
(3
9%
) Co
CO
CO
CO
CM 45 
(6
4%
)
22 
(3
1%
)
Su
rv
iv
or
s
(n
=2
00
)
Nu
m
be
r, 
%
 
of 
su
rv
iv
or
s
35 
(1
3-
53
)
12
1 
(6
1%
)
10
1 
(7
5%
) 
(n
=1
34
)
72 
(5
4%
) 
(n
=1
34
)
2(
1%
)
81 
(4
1%
)
31 
(1
6%
)
20 
(1
0%
)
12 
(6
%
)
5 
(3
%
)
8 
(4
%
)
157
 
(7
9%
)
18
(9
%
)
25
(1
3%
)
19
(1
0%
)
175
 
(8
8%
) C?
CO
CM
CO
O
ve
ra
ll
(n
=2
70
)
Nu
m
be
r, 
% 
of
 
ov
er
al
l 
pa
tie
nt
s
39 
(1
4-
60
)
163
 
(6
0%
)
147
 
(7
7%
) 
(n
=1
91
)
102
 
(5
3%
) 
(n
=1
91
)
7(
3%
)
13
1 
(4
9%
)
Co0 s
CO
CM 30 
(1
1%
)
25 
(9
%
)
24 
(9
%
) Co0sCO,
COT— 19
1 
(7
1%
)
27
(1
0%
)
52 
(1
9%
)
42 
(1
6%
) Cp0s
CO
o
CM
CM
Cp
COCD
COT—
De
m
og
ra
ph
ic
s
Ag
e 
(y
ea
rs
); 
me
dia
n 
(IQ
R)
Se
x 
(m
al
e)
M
an
ua
l l
ab
ou
r*3
 
(if 
ag
ed
 
ov
er
 1
6 
ye
ar
s)
- R
ice
 
fa
rm
in
g*
3
Co
-m
or
bi
di
tie
s
Pr
em
at
ur
ity
/ 
Ve
ry 
low 
bir
th 
w
ei
gh
t
Un
de
rly
ing
 
m
ed
ica
l c
on
di
tio
ns
*4
- D
iab
et
es
 
m
el
litu
s
- I
m
m
un
os
up
pr
es
sio
n*
3
- R
en
al 
di
se
as
e*
6
- C
ar
dia
c 
di
se
as
e*
- L
un
g 
di
se
as
e
So
ur
ce
 
of 
in
fe
ct
io
n
Co
m
m
un
ity
-a
cq
ui
re
d
No
n-
no
so
co
m
ia
l 
he
al
th
ca
re
-a
ss
oc
ia
te
d
No
so
co
m
ia
l D
ru
g 
re
si
st
an
ce
M
RS
A
In
te
rv
en
tio
ns
Ef
fec
tiv
e 
an
tib
iot
ic 
the
ra
py
 
wi
th
ou
t 
de
la
y
Pr
oc
ed
ur
e 
for
 i
nf
ec
tio
us
 
so
ur
ce
 
co
nt
ro
l
00
Da
ta 
are
 
nu
m
be
r 
(%
) 
un
les
s 
oth
er
wi
se
 
st
at
ed
.

Ta
ble
 
4.2
: 
Th
e 
ra
ng
e 
of 
sit
es
 
of 
in
fe
ct
io
n 
in 
pa
tie
nt
s 
an
d 
ou
tc
om
e 
as
so
ci
at
ed
 
wi
th 
ea
ch
 
cl
in
ic
al
 p
re
se
nt
at
io
n
At
tri
bu
ta
bl
e 
p 
va
lu
e*
2
oo
dV <0
.0
01
<0
.0
01
eooo
COCO
CD
d 0.
31
3
0.
59
6
<0
.0
01
S. 
au
re
us
- 
at
tri
bu
ta
bl
e 
de
at
hs
 
(n
=5
5)
Nu
m
be
r, 
% 
of
 
at
tri
bu
ta
bl
e 
de
at
hs
20 
(3
6%
)
31 
(5
6%
)
4 
(7
%
)
45 
(8
2%
)
1 
(2
%
)
2 
(4
%
)
7(
13
%
)
3 
(5
%
)
6(
11
%
)
12 
(2
2%
)
Al
l-c
au
se
 
p 
va
lu
e*
1
<0
.0
01 oo
oV
oo
oV
oo
d
CO
d
CO
CDO
d
o
CD
d
oo
dV
Al
l-c
au
se
 
de
at
hs
 
(n
=7
0)
_
Nu
m
be
r, 
% 
of 
al
l 
de
at
hs COCO
CO
CM 43 
(6
1%
)
4 
(6
%
) Cp
CD
CO
ID
1 
(1
%
)
4(
6%
)
11 
(1
6%
)
3 
(4
%
)
7(
10
%
)
16
(2
3%
)
Su
rv
iv
or
s
(n
=2
00
)
Nu
m
be
r, 
% 
of
 
su
rv
iv
or
s
0s
CO
15
7 
(7
9%
)
27 
(1
4%
)
47 
(2
4%
) Co
CMCO 40 
(2
0%
)
19
(1
0%
) Cpo'
CM
''tf-
CM 1
7(
9%
)
6 
(3
%
)
To
ta
l 
no
. 
of
 
pa
tie
nt
s 
(n
=2
70
)
Nu
m
be
r, 
%
 
of 
ov
er
al
l 
pa
tie
nt
s
39 
(1
4%
)
"tf-
OO
CM 31
 
(1
1%
)
10
0(
37
%
) 
|
83 
(3
1%
)
44
(1
6%
)
30
(1
1%
)
27 
(1
0%
)
24 
(9
%
) 5^CO
CM
CM
To
ta
l 
no
. 
of
 
si
te
s 
(n
=2
64
)
Nu
m
be
r, 
%
 
of 
all
 s
ite
s
89 
(3
4%
)
46 
(1
7%
)
31 
(1
2%
)
30
(1
1%
)
CD COCO
24 
(9
%
)
O500 COCM - -
I 
23 
(9
%
)
CM -
Cl
in
ic
al
 p
re
se
nt
at
io
ns
Pa
tte
rn
 
of 
di
se
as
e
Ba
cte
ra
em
ia 
on
ly,
 n
o 
ide
nti
fie
d 
site
 
of 
in
fe
ct
io
n
1 
ide
nti
fie
d 
site
 
of 
in
fe
ct
io
n
>1 
ide
nti
fie
d 
site
 
of 
in
fe
ct
io
n
Blo
od
 
cu
ltu
re
 
po
sit
ive
Su
pe
rfi
ci
al
 a
bs
ce
ss
es
 
(sk
in 
an
d 
so
ft 
tis
su
e)
De
ep
 
ab
sc
es
se
s*
Ot
he
r 
sk
in 
an
d 
so
ft 
tis
su
e 
in
fe
ct
io
ns
*4
Bo
ne
 
an
d 
jo
in
t 
in
fe
ct
io
ns
- S
ep
tic
 
ar
th
rit
is
- O
st
eo
m
ye
liti
s
- D
iab
eti
c 
foo
t 
in
fe
ct
io
n
Pr
os
th
et
ic
 
m
at
er
ia
l 
in
fe
ct
io
ns
- O
rth
op
ae
dic
 
m
at
er
ia
l*5
- I
nt
ra
ve
no
us
 
de
vic
e*
5
- P
ac
em
ak
er
- M
en
ing
itis
 
re
lat
ed
 
to 
ve
nt
ric
ul
os
to
m
y 
dr
ai
n
- A
rte
rio
ve
no
us
 
gr
af
t
- P
er
ito
nit
is 
from
 
pe
rit
on
ea
l d
ia
lys
is
Re
sp
ira
to
ry
 
in
fe
ct
io
ns
- P
ne
um
on
ia ro
E<D>>Q.
ELU1
0.
66
7 'a-COCD
d 0.
10
1
2 
(4
%
) Co"o'
CM 3 
(5
%
)
. 
>0
.9
99 OCOCO
d 0.
18
2
o'-CO
CM 3 
(4
%
)
3 
(4
%
)
6(
3%
)
4 
(2
%
)
3 
(2
%
)
O'CO
CO 7 
(3
%
)
6 
(2
%
)
8 
(3
%
)
7 
(3
%
)
6 
(2
%
)
En
do
ca
rd
iti
s*
7
Ot
he
r 
in
fe
ct
io
ns
*8
Po
st
-o
pe
ra
tiv
e 
in
fe
ct
io
ns
*8
4.2.6 Drug resistance
MRSA accounted for 16% (n=42) of infections overall, increasing to 26% in those patients 
with bacteraemia. There was no significant difference in the MRSA rates between adults 
and children. No community-acquired MRSA was identified, the MRSA infections being 
defined as nosocomial (n=29, 69%), or non-nosocomial healthcare-associated (n=13, 
31%). MSSA infections were predominantly community-acquired (84%, n=191), the 
remainder being nosocomial (n=23,10%) or non-nosocomial healthcare-associated 
(n=14, 6%). MRSA infection was positively associated with all-cause death; 19/200 (10%) 
patients who survived were infected with MRSA compared with 23/70 (33%) of those who 
died (p<0.001) (Figure 4.1), and the association remained highly significant for attributable 
mortality (p=0.001).
4.2.7 Antibiotic therapy
Antibiotic therapy was prescribed to 269/270 patients, the single exception being a patient 
who was discharged from hospital prior to the culture results becoming available. The 
majority (n=253, 94%) of patients started antibiotics on or before the day their positive 
culture was taken. Of these, 220 patients (87%) received an empiric antibiotic that 
covered their infecting strain of S. aureus as judged by in vitro susceptibility testing. Of the 
remainder, 42 patients had a delay in starting antibiotic therapy to which the organism was 
susceptible (median delay 3 days, IQR 2-4 days), and 7 patients never received an 
effective antibiotic. A delay in receiving effective antibiotic therapy or never receiving 
effective therapy was significantly associated with an increased all-cause mortality (50% 
vs. 20%, p<0.001) (Figure 4.2) and attributable mortality (p<0.001).
4.2.8 Infectious source control
A procedure for infectious source control was performed in 184 patients (68%). This was 
associated with a significantly improved outcome: mortality with and without a procedure 
was 12% and 56%, respectively (p<0.001) (Figure 4.2). The procedures were: needle 
aspiration (n=10), incision and drainage (n=109), debridement (n=35), joint washout (n=8),
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removal of prosthesis (n=7), thoractomy/ decortication (n=4), nephrectomy (n=3), 
laminectomy (n=2), chest drain (n=2), above knee amputation (n=1), fasciotomy (n=1), 
ethmoidectomy (n=1) and craniectomy with removal of infected bone flap (n=1).
4.2.9 Panton-Valentine Leukocidin
The infecting S. aureus isolates from 248 patients were available for PCR, of which 122 
(49%) were positive for the genes encoding PVL, all of which were MSSA. The white cell 
count at the time of culture was not significantly different between PVL gene-positive and 
PVL gene-negative cases (median 15.30 x109/L vs. 14.69 x109/L, respectively, p=0.38). 
The distribution of clinical presentations and outcome in relation to PVL status is shown in 
Table 4.3. PVL gene-positive isolates were significantly more likely to cause skin and soft 
tissue abscesses (p<0.001) and deep abscesses (p=0.001) than PVL gene-negative 
isolates. A significant negative association was observed between the presence of PVL 
genes and bacteraemia without a localising site of infection (p<0.001), prosthetic material 
infections (p<0.001) and other skin and soft tissue infections (p=0.026). Additionally, there 
was a highly significant negative association between the presence of PVL genes and all­
cause mortality: mortality was 11 % amongst PVL gene-positive cases and 39% in PVL 
gene-negative cases (p<0.001) (Figure 4.1) as well as S. aureus-attributable mortality 
(p<0.001). This association remained highly significant when adjusted for MRSA cases 
(p=0.001). The outcome from pneumonia was poor regardless of PVL gene carriage: 
mortality was 80% for PVL gene-positive cases and 83% for PVL gene-negative cases.
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Figure 4.1: Association between all-cause mortality and methicillin-resistant S.
aureus (MRSA) and Panton-Valentine Leukocidin (PVL).
Patients infected by MRSA had a greater all-cause mortality compared with patients 
infected by methicillin-susceptible S. aureus (MSSA) (p<0.001). Conversely, patients 
infected by PVL gene-positive S. aureus had a lower all-cause mortality compared with 
patients infected by PVL gene-negative S. aureus (p<0.001), an association that remained 
after adjustment for MRSA (p=0.001).
60
'
30
MSSA MRSA PVL positive PVL negative
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Figure 4.2: Association between all-cause mortality and timely effective antibiotic
therapy and procedures for infectious source control.
Administration of an effective antibiotic on the same day as the positive culture was taken 
significantly reduced all-cause mortality (p<0.001), as did undergoing a procedure for 
infectious source control (p<0.001).
60
50
40
30
20
10
Timely effective Delayed antib iotic Procedure 
antib iotic therapy therapy*
No procedure
* Delayed antibiotic therapy included 7 patients who never received an effective antibiotic.
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4.2.10 Risk factors for mortality
All variables in Tables 4.1 and 4.2 found to be significantly associated with all-cause and 
attributable mortality on univariable testing and with 5 or more events (deaths) together 
with the presence of PVL genes, were analysed further using multiple logistic regression 
to give the final models shown in Table 4.4. Cardiac, renal and lung disease were 
considered as separate variables for all-cause mortality, and cardiac and renal disease for 
attributable mortality. Only cardiac disease remained in each of the final models. Age, 
underlying cardiac disease and respiratory infection were positively associated with all­
cause mortality, while one or more abscesses (deep and superficial combined) as the 
presenting clinical feature and a procedure for infectious source control were negatively 
associated with all-cause mortality. An analysis of S. aureus-attributable mortality 
demonstrated the same associations. Underlying cardiac disease and respiratory infection 
had the highest odd ratios for both all-cause mortality and S. aureus-attributable mortality.
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4.3 Discussion
This prospective study generated much more detailed and informative data regarding 
invasive S. aureus disease in a resource-restricted tropical setting. The study adds to the 
evidence base that S. aureus is an important pathogen in developing countries in the 
tropics as it gives rise to considerable morbidity and mortality. The inclusion of cultures 
from all normally sterile sites rather than merely blood cultures yielded a more diverse 
range of clinical manifestations which mirrored those described from developed temperate 
countries. In particular, infections such as osteomyelitis, solid organ abscesses and 
endocarditis which had been absent or poorly represented in the retrospective study of S. 
aureus bacteraemia, accounted for a greater number of infections. The wider inclusion 
criteria also meant that there was no longer an apparent lack of investigations for pus 
collections and procedures for pus drainage.
The mortality rate for bacteraemia was again considerably higher than that 
reported from well resourced healthcare settings in Europe and the United 
States,52,161,479,483 with the majority of deaths being attributable to S. aureus. In the 
developed world, factors associated with poor outcome from S. aureus infection include 
increasing age,297,479 underlying co-morbidities 484 antimicrobial resistance 485 complicated 
(disseminated) bacteraemia 486 lack of source control297 including non-removal of 
intravenous catheters,298 under-dosing of penicillinase antibiotics for methicillin- 
susceptible S. aureus (MSSA),297 and delayed antibiotic therapy.186 The relevance of 
these findings for the developing world has not yet been directly addressed in the 
published literature. This study demonstrated that many of these same factors were 
relevant for predicting mortality in a resource-restricted tropical setting; namely increasing 
age; underlying co-morbidities, in particular cardiac, renal and lung disease; methicillin 
resistance; lack of source control and delayed antibiotic therapy. Although in the 
retrospective study it was not possible to determine whether underlying co-morbidities 
were a confounding factor for the higher mortality seen with increasing age, the data from 
this study indicate that underlying co-morbidities are not a significant confounding factor. 
An awareness of those patient groups at high risk for death can have considerable clinical
59
utility in settings where healthcare facilities are available but limited and healthcare 
workers have a large patient caseload. Since the significant risk factors for death were 
data that are readily available without extra expense, identification of these risk factors is 
a practical option for those working in resource-restricted settings.
This hospital-based study conducted in provincial Thailand is relevant to the 
numerous developing countries with growing economies and expanding healthcare 
facilities, many of which are in South and East Asia, where it is possible to identify 
patients with suspected bacterial sepsis, administer empiric, broad-spectrum antibiotics, 
and drain pus collections. Practical, inexpensive solutions are needed to improve the 
outcome of bacterial sepsis in such developing country settings. A shorter time to the first 
dose of effective antibiotics has been related to a better outcome for a range of bacterial 
infectious diseases, including S .aureus, in the developed world,186,294,315 and held true in 
this study of S. aureus infection. Another low cost intervention is drainage of pus which is 
advocated as the standard of care elsewhere296 and would be predicted to reduce poor 
outcomes in developing country settings as well. Although both the low cost interventions 
of timely antibiotic therapy and drainage of pus collections were significantly associated 
with an improved outcome on univariate analysis, only procedures for infectious source 
control remained in the final model from multivariate analysis. This may be influenced by 
the fact that skin and soft tissue abscesses were the most common presentation and 
drainage of superficial pus collections can result in cure irrespective of antibiotic 
therapy.295 Antibiotic therapy in bacteraemic patients is analysed further in Chapter 5. This 
study indicates that identification of abscesses and drainage of pus is fundamental to 
sepsis control, and the use of available imaging to investigate patients with S. aureus 
sepsis and guide drainage procedures should be a priority. The higher mortality observed 
in our study for patients with bacteraemia in whom a site other than bloodstream was not 
identified is consistent with the higher mortality in patients who had a focus but no 
procedure for source control, and with the survival benefit for patients who underwent a 
procedure.
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Nosocomial infection and drug resistance are the focus of enormous research 
efforts and expenditure in the developed world. In developing countries worldwide, these 
are generally poorly understood although there is wide variability. The importance of both 
nosocomial infection and drug resistance were highlighted in this study. Nearly one third 
of infections were nosocomial or non-nosocomial healthcare-associated, and patients in 
these groups had significantly higher mortality rates for both all-cause and S. aureus- 
attributable deaths. Infection with MRSA was either nosocomial or non-nosocomial 
healthcare-associated, and was independently associated with all-cause and attributable 
mortality. Given the importance of these findings, delineating the group of patients with 
non-nosocomial healthcare-associated infections was clearly a critical improvement in the 
prospective data. Those patients affected by healthcare-associated infection often have 
other risk factors for death such as prematurity, old age, underlying medical conditions or 
have undergone recent surgery and the high mortality rate is not surprising. However, 
healthcare-associated infections and infection-related deaths are potentially preventable 
and so there is a clear need for studies in resource-restricted tropical settings that 
evaluate the transmission of antibiotic resistance pathogens, such as MRSA, and low cost 
preventive interventions such as a hand hygiene campaign.
Nearly half of isolates causing S. aureus infection in patients presenting to our 
hospital were PVL gene-positive, which is significantly higher than that for previous 
reports for infecting isolates amongst blood culture and skin infection samples from 
Malaysia (5%),487 skin infections in Bangladesh (14.3%),488 and blood culture (2.1%) and 
soft tissue infection samples (38.9%) from the Netherlands.489 This may imply that PVL 
gene-positive strains are more likely to cause infection than PVL gene-negative isolates 
(that is, the rate of PVL gene-positivity is lower in carriage than invasive strains). This 
could either be a function of the presence and action of PVL per se, or could relate to one 
or more alternative genes associated with disease acquisition that is in genetic linkage 
with the genes encoding PVL.
The role of PVL as a putative virulence determinant is a hotly debated topic within 
the staphylococcal community, and this led me to examine the association between this
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and both clinical presentations and outcome. The study design was robust in that all 
patients with S. aureus infection who required hospital treatment were recruited. Previous 
reports have been based on patient subsets determined by clinical presentation,248 culture 
sample type253 or by being sent to a reference laboratory.266 The single most important 
finding was that PVL gene-positive isolates were strongly associated with patient survival 
compared to PVL gene-negative isolates. This may be explained in large part by the fact 
that PVL gene-positive isolates were associated with skin and soft tissue abscesses, an 
association reported previously266,274,490 and a clinical manifestation associated with low 
morbidity. Community-acquired PVL-associated necrotising pneumonia affecting 
previously fit people is often fatal and has gained considerable notoriety. In this study 
there were 3 patients (1%) with PVL gene-positive, community-acquired pneumonia who 
were previously healthy individuals. None of these patients had haemoptysis, which is 
deemed a major diagnostic criterion for PVL-associated necrotising pneumonia,491 
although none of the prospective cases in the original paper by Gillet et al describing PVL- 
associated necrotising pneumonia were described as having had haemoptysis.248 Two out 
of 3 of these patients died, but this was in the context of a very high mortality of more than 
80% for S. aureus pneumonia overall. Although further cohort studies of unselected 
patients are needed to determine the role of PVL as a virulence factor in other geographic 
settings, the current study provides no support for rapid PVL testing in this and other 
developing country settings, where the focus should firmly rest with clinical interventions 
that save lives.
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Chapter 5. Prospective study of outcome from bacteraemia and impact of drug
resistance on antibiotic prescribing
5.1 Chapter content
The prospective clinical study undertaken in the study hospital in northeast Thailand was 
based on the study of S. aureus bacteraemia carried out in the USA by Fowler et al.161 
The similarity of design allowed for a comparison of S. aureus bacteraemia between a 
well-resourced temperate setting (USA) and a resource-restricted tropical setting 
(northeast Thailand). This chapter focuses on the subset of 98 patients with bacteraemia 
from the cohort of 270 prospectively identified patients with invasive S. aureus disease. 
The study methods were described in Chapter 2.
5.2 Results
5.2.1 Patient characteristics
Over the 1 year study period a total of 106 patients were identified with at least one 
clinically significant blood culture positive for a pure growth of S. aureus. Of these, 98 
patients were recruited and 8 patients could not be studied either because they declined 
consent (n=6) or because they left the hospital for Lao PDR (across the Mekong River 
from Thailand) before the culture became positive and follow-up was not possible (n=2). 
The patient characteristics are shown in Table 5.1. The age of enrolled patients ranged 
from 1 day to 92 years (median 39 years). There were 61 (62%) adult and 37 paediatric 
patients (less than 18 years). There was a slight preponderance of males (58%) but this 
difference was not statistically significant. A history of one or more underlying chronic 
medical conditions was documented in 57 cases (58%), with cardiac disease accounting 
for the greatest proportion (20 cases).
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Table 5.1: Patient characteristics
All patients (n=98)
Number of patients (percent)
Demographics
Age (years), median (interquartile range) 39 (9 -  65)
Sex (male) 57 (58%)
Thai nationality 96 (98%)*1
Co-morbidities
Prematurity/ Very low birth weight 5 (5%)
(29% of those aged under 1 year)
Intravenous drug use 4 (4%)
Underlying medical conditions 57 (58%)
- Cardiac disease 20 (20%)
- Diabetes mellitus 12(12%)
- Renal disease 11(11%)
- Immunosuppression*2 11(11%)
- Lung disease 6(6%)
Place of acquisition
Community-acquired 44 (45%)
Nosocomial 40(41%)
Non-nosocomial healthcare-associated 14 (14%)
*1 Two patients were from Lao PDR
*2 Immunosuppression from chemotherapy (n=4), untreated leukaemia (n=1), HIV (n=3, 
none of whom were on anti-retroviral therapy or any prophylactic antibiotics) or 
immunosuppressive medication including prednisolone >30mg/ day for >1 week (n=4; one 
of these additionally on chemotherapy)
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5.2.2 Types of infection
A site of infection was identified in 59 (60%) patients. Of the 13 patients with more than 1 
site of infection, 12 had 2 sites and 1 had 3 sites identified. There was a diverse spectrum 
of disease manifestations as shown in Table 5.2. The most common sites of infection 
were skin and soft tissue infection (18 sites, 25% of all sites) and pneumonia (12 sites, 
16%).
5.2.3 Healthcare exposure
Over half of the infections (55%) were either nosocomial or non-nosocomial healthcare- 
associated (Table 5.1). Nosocomial infections were most common in those aged less than 
1 year old, accounting for 94% of cases. Infections related to devices were the third most 
common site of infection, accounting for 14% of all sites. Additionally 4 patients had 
mediastinitis following thoracic surgery.
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Table 5.2: Sites of infection
Types of disease All patients (n=98)
Number of patients (percent)
No identified site of infection 39 (40%)
1 identified site of infection 46 (47%)
>1 identified site of infection 13(13%)
Sites of infection All sites (n=73)
Number of sites (percent)
Skin and soft tissue infection 18 (25%)
Pneumonia 12(16%)
Device-related infection*1 10(14%)
Endocarditis*2 8(11%)
Septic arthritis 7(10%)
Post-operative mediastinitis*3 4 (5%)
Other lung infection*4 4 (5%)
Solid organ abscess*5 3 (4%)
Osteomyelitis 2 (3%)
Pyomyositis 2 (3%)
Diabetic foot infection 2 (3%)
Urinary tract infection 1 (1%)
*1 Intravenous catheters (central n=3, peripheral n=2, umbilical n=1), pacemakers (n=3) 
and arteriovenous graft (n=1)
*2 Vegetations on transthoracic echocardiography (n=7); or strong clinical evidence in 
intravenous drug user (n=1)
*3 Following mitral valve replacement (n=3), or coronary artery bypass graft (n=1)
*4 Empyema (n=2), septic emboli to the lungs (n=1), lung abscesses (n=1)
*5 Liver (n=2), spleen (n=1)
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5.2.4 Prevalence of endocarditis
Transthoracic echocardiography was performed in 49 out of 98 patients (50%). Although 
the aim of the study was to perform transthoracic echocardiography on all patients, the 
remaining 49 patients either were discharged or died before an echocardiogram could be 
performed, were too sick to be taken to the echocardiography room, had a 
contraindication to transthoracic echocardiography, or the echocardiography machine or 
trained personnel were not available. However, there were no significant differences 
between those who did and did not undergo echocardiography in terms of pre-disposing 
cardiac conditions, co-morbidities, immunocompromise, age or presence of prosthetic 
material (data not shown). Seven of the 49 patients (14%) undergoing transthoracic 
echocardiography had vegetations visualised. The affected heart valves were mitral (n=3), 
aortic (n=3) and tricuspid (n=1). Two patients had definite endocarditis and 5 had possible 
endocarditis by modified Duke criteria,492 since taking 2 blood culture bottles is uncommon 
in the hospital. Among these 7 patients with endocarditis, 1 died. One additional patient 
with a history of injection drug use met clinical criteria for endocarditis, but died before 
echocardiography could be performed.
5.2.5 Persistent blood culture positivity
In addition to transthoracic echocardiography, the other study-specific investigation was 
taking a repeat blood culture within 48-96 hours of the first culture positive for S. aureus. A 
repeat blood culture was taken in 57 patients (58%, representing 79% of patients 
surviving to 4 days), of which 11 (19%) were still positive for S. aureus. After this time 
period, 56 further blood cultures were taken from 23 patients, which identified an 
additional 3 patients with persistently positive blood cultures. No vegetations were seen 
on transthoracic echocardiography performed on 11 of these 14 patients with persistently 
positive cultures. MRSA was responsible for persistently positive cultures significantly 
more often than MSSA infection (30% versus 8% respectively (p=0.02)). Eight of 14 
patients (57%) were receiving antibiotic therapy to which the organism was susceptible in 
vitro at the time the repeat blood culture was taken.
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5.2.6 Antibiotic resistance and therapy
MRSA accounted for 28% (n=27) of S. aureus bacteraemias, with no significant difference 
in rate between adults and children (26% versus 30% respectively; p=0.82). The MRSA 
cases were either nosocomial (n=21, 78%) or non-nosocomial healthcare-associated 
(n=6, 22%). Of the 71 MSSA cases, 44 (62%) were community-acquired, 8 (11%) were 
non-nosocomial healthcare-associated, and 19 (27%) were nosocomial. Although MRSA 
cases occurred throughout the hospital, there was a significant difference in MRSA rates 
on the intensive care units compared with the general wards: 57% versus 16%, 
respectively (p<0.001).
The impact of MRSA on effective prescribing of antibiotic therapy is summarised in 
Table 5.3. Patients infected with MSSA were more likely than patients infected with MRSA 
to receive an antibiotic to which the organism was susceptible before the culture results 
became available (67/71 (94%) versus 4/27 (15%) respectively, p<0.001). The median 
number of days to starting antibiotic therapy to which the organism was susceptible in 
vitro was 0 (IQR 0-0) days and 3 (IQR 2-4) days for MSSA and MRSA, respectively 
(p<0.001). Once culture results were available, 70 out of 73 survivors (96%) received an 
antibiotic that covered the infecting isolate. The median duration of parenteral treatment 
given to survivors from the day the first culture positive for S. aureus was taken was 17 
(IQR 12-24) days, with no difference in duration for patients infected with MSSA versus 
MRSA (p=0.26).
All MRSA isolates were susceptible to vancomycin by E-test (minimum inhibitory 
concentration £ 2pg/ml). Of the 17 patients with normal renal function who received 
vancomycin, 13 (76%) received adequate vancomycin doses by manufacturer’s 
recommendations. Measurement of vancomycin drug levels was not available in the 
hospital. Antibiotic resistance patterns are summarised in Table 5.4. Over 90% of MRSA 
isolates were resistant to ciprofloxacin, erythromycin, gentamicin, netilmicin, tetracycline 
and trimethoprim-sulphamethoxazole, and 65% were resistant to clindamycin.
Vancomycin and fusidic acid had the lowest rates of resistance.
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Table 5.3: Impact of methicillin-resistant S. aureus (MRSA) on effective antibiotic 
prescribing
All patients 
(n=98)
MSSA*1
(n=71)
MRSA*1
(n=27)
value*2
Number of patients (percent)
Pre-culture results
Antibiotic therapy prescribed 93 (95%) 67 (94%) 26 (96%) >0.99
Infecting strain of S. aureus 
susceptible to prescribed 
antibiotic
71 (72%) 67 (94%) 4(15%) <0.001
Optimal antibiotic therapy*3 25 (26%) 23 (32%) 2 (7%) 0.01
Post-culture results*4 All patients 
(n=73)
MSSA
(n=50)
MRSA
(n=23)
Antibiotic therapy prescribed 72 (99%) 49 (98%) 23 (100%) >0.99
Infecting strain of S. aureus 
susceptible to prescribed 
antibiotic
70 (96%) 48 (96%) 22 (96%) >0.99
Optimal antibiotic therapy*3 53 (73%) 32 (64%) 21 (91%) 0.02
*1 MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus 
*2 p value comparing MSSA and MRSA groups
*3 Optimal therapy defined as cloxacillin for MSSA infection and vancomycin for MRSA 
infection. Alternative therapy used included ceftriaxone, cefazolin, cefoxitin, ceftazidime, 
augmentin and ampicillin combined with gentamicin.
*4 Denominator is patients who survived to day of culture result. A total of 25 patients (21 
with MSSA and 4 with MRSA) died or were discharged moribund prior to culture results 
becoming available
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Table 5.4: Antibiotic resistance rates for infecting isolates
Antibiotic All isolates (n=81) MSSA*1 (n=58) MRSA*1 (n=23)
Number of resistant isolates (%)
Chloramphenicol 8(10%) 4 (7%) 4(17%)
Ciprofloxacin 22 (27%) 1 (2%) 21 (91%)
Clindamycin 16 (20%) 1 (2%) 15(65%)
Erythromycin 25 (31%) 2 (3%) 23(100%)
Fusidic acid 42 (52%) 39 (67%) 3(13%)
Gentamicin 23 (28%) 0 23 (100%)
Mupirocin 7 (9%) 2 (3%) 5 (22%)
Netilmicin 21 (26%) 0 21 (91%)
Penicillin 80 (99%) 57 (98%) 23(100%)
Rifampicin 8(10%) 0 8 (35%)
Tetracycline 56 (69%) 34 (59%) 22 (96%)
Trimethoprim-
sulphamethoxazole
22 (27%) • 0 22 (96%)
Vancomycin 0 0 0
*1 MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus
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5.2.7 Mortality
The overall mortality rate at 12 weeks was 52% (n=51), and the S. aureus attributable 
mortality rate was 44% (n=43). In 1 case there was insufficient information to determine 
the cause of death. Most deaths (39/51, 76%) occurred in hospital or at home on the day 
of discharge, as relatives commonly take moribund patients home to die (n=12). S. aureus 
bacteraemia accounted for 1 % of all in-patient deaths at Sappasithiprasong hospital 
during the study period.
Overall mortality increased significantly with age (p<0.001) (Figure 5.1). There was 
a significant difference between the overall mortality rate in children compared to adults 
(32% versus 64%, p=0.003). The association between overall mortality and increasing 
age remained highly significant when adjusted for underlying co-morbidities or 
immunosuppression (p=0.001). The mortality rates for MRSA and MSSA were 67%
(18/27) and 46% (33/71), respectively (p=0.11). There was no significant difference in 
mortality between patients with and without identified sites of infection, (47% and 59% 
respectively, p=0.31). Mortality amongst patients with repeated blood cultures positive for 
S. aureus was 43% (6/14). The median number of days to death in those patients whose 
death was attributable to S. aureus was 3 (IQR, 1-6) days compared with 47 (IQR, 25-68) 
days in those with non-attributable deaths (p<0.001). Significant differences were noted 
on survival curve analysis of attributable mortality rates in adults and children (p=0.01) 
(Figure 5.2), and in the timing of death for S. aureus attributable and non-attributable 
deaths (p=0.001) (Figure 5.3). There was no difference in times to death comparing 
patients infected with MSSA versus MRSA (data not shown). At 12 weeks, 44 patients 
(45%) were cured, and 3 patients (3%) had unresolved infection (empyema thoracis, 
infected pacemaker, and osteomyelitis).
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Figure 5.1: Age distribution and age-specific mortality rates and disease burden for 
98 cases of S. aureus bacteraemia.
The burden of S. aureus bacteraemia is highest at the extremes of age, whilst mortality 
increased significantly with age (p<0.001), analysing age as a continuous variable.
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Figure 5.2: Kaplan-Meier survival curves comparing adult and paediatric patients
with respect to S. aureus-attributable deaths.
Survival from S. aureus bacteraemia is worse in adults than in children. (p=0.01). Non- 
attributable deaths were censored.
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Figure 5.3: Kaplan-Meier survival curves comparing S. aureus attributable deaths
and non-attributable deaths.
S. aureus attributable deaths occur more rapidly than non-attributable deaths (p=0.001).
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5.3 Discussion
This prospective study reinforces the view that S. aureus bacteraemia is an important 
cause of morbidity and mortality in northeast Thailand. The all-cause and S. aureus- 
attributable mortality rates in this study, 52% and 44% respectively, were considerably 
higher than mortality rates for S. aureus bacteraemia generally reported from 
industrialised temperate countries.479,483,493 In comparison with the similarly designed 
study of S. aureus bacteraemia conducted in the USA by Fowler et al161, the mortality 
rates in Thailand were roughly double. Fowler et al found an all-cause and attributable 
mortality of 22% (157/724) and 12% (86/724), respectively, but they excluded deaths that 
occurred before culture results were available. The addition of these cases would have 
given an all-cause and S. ai/reus-attributable mortality rate of 33% and 23%, respectively.
These data on the importance of S. aureus bacteraemia as a cause of morbidity 
and mortality in a resource-restricted tropical setting are supported by published studies of 
all-cause bacteraemia in Asia, which have identified S. aureus as a major cause of 
bacteraemia, accounting for both community-acquired and hospital-acquired 
disease.8,494,495 Extrapolating further, if these data showing that S. aureus accounted for 
1% of all in-patient deaths is representative of this populous region (half the world’s 
population lives within a 2000 mile radius of northeast Thailand), then S. aureus would be 
a major contributor to preventable mortality worldwide. When this work was published it 
was the first published prospective study to focus on S. aureus bacteraemia in a resource- 
restricted tropical setting in Asia to my knowledge, having reviewed the literature. This 
was particularly noteworthy because papers describing all-cause bacteraemia in Asia 
rarely gave details by causative organism, resulting in an under-appreciation of the 
morbidity and mortality burden due to S. aureus in the tropics.
In this prospective study, S. aureus bacteraemia was most common at the 
extremes of age, a similar pattern to that described in a temperate industrialised 
country.52,53 The comparative study by Fowler et al161 did not include patients aged less 
than 18 years so the age structure of study participants cannot be compared. Additionally, 
because Sappasithiprasong Hospital is the regional hospital for the province with referrals
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from clinics and hospitals in the province but also provides primary care services to a 
large local population, accurate estimates of disease incidence were not possible. Among 
the 17 patients under 1 year of age, 16 (94%) had hospital-acquired infections and nearly 
a third (29%) were premature or very low birth weight babies. This indicates that children 
less than 1 year of age who require multiple interventions and a prolonged stay in hospital 
are at particular risk of nosocomial S. aureus bacteraemia. A higher incidence in those 
aged under 1 year and the predominance of nosocomial infections in this age group has 
been described in Denmark.53 The increase in number of cases and mortality with age 
also mirror the rise in co-morbidities with age, as noted in Denmark.52
A broader range of clinical manifestations of S. aureus bacteraemia was seen 
compared with the retrospective study, as hypothesised given the increased detail 
obtainable with a prospective study. The findings mirrored more closely the diversity of 
clinical manifestations described for patients with S. aureus bacteraemia in temperate 
industrialised countries. Interestingly, the 2 most common manifestations (skin and soft 
tissue infection followed in frequency by pneumonia) were the same in the both the 
retrospective and prospective studies in spite of the greater diversity of manifestations in 
the latter. The study findings suggested that the burden of S. aureus disease in the tropics 
exceeded current perceptions, and demonstrated that serious invasive infections were 
common. This has an important bearing on antimicrobial therapy because management of 
deep infections and bacteraemia requires effective antimicrobial therapy whereas 
drainage of superficial pus collections can result in cure irrespective of antibiotic 
therapy.295 Over half of the patients had healthcare-associated infections and device­
related infections were the third most common site of infection, suggesting that S. aureus 
bacteraemia in Thailand was strongly related to healthcare, thereby reflecting the situation 
in industrialised temperate countries.161,496,497
The rapid deterioration and short median time to death (3 days) of patients dying 
from S. aureus septicaemia meant that echocardiograms could not be performed on many 
of the patients. However, the prevalence of echocardiographically-confirmed endocarditis 
of 14% (7/49) was comparable to that seen in industrialised temperate countries,161,498
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which has important implications for many tropical countries where restricted or delayed 
access to echocardiography is liable to be an issue. The study prevalence may have been 
an underestimate since those patients who died earlier may have been more likely to have 
endocarditis. A quarter of the patients with endocarditis died, which was at the lower end 
of the mortality range reported for S. aureus endocarditis (25-47%)482 and may have been 
a further indication that a number of patients who died prior to echocardiography had 
undiagnosed endocarditis. The heart valves affected by endocarditis were predominantly 
left-sided, which was in keeping with the low number of intravenous drug users in the 
study. Half the patients with endocarditis were teenagers, which was a younger age group 
than typically seen in industrialised temperate countries482,499 but is described in other 
tropical countries,90,500 often as a result of rheumatic heart disease and uncorrected 
congenital heart disease. However, none of the patients with endocarditis in this study had 
known valvular abnormalities.
MRSA was responsible for nearly one third of cases of S. aureus bacteraemia, all 
of which were healthcare-associated. Although community-associated MRSA is a major 
problem elsewhere, there was no evidence found for this in the study hospital where a 
clone defined by multilocus sequence typing as sequence type 239 predominated,224 
which has been strongly associated with healthcare acquisition. Although there were 
comprehensive hospital infection control guidelines in Sappasithiprasong hospital, 
implementing these was difficult due to a bed occupancy rate that often exceeded 100% 
and a lack of infrastructure, such as a scarcity of isolation rooms and only two hand wash 
basins on each of the general wards. Since over half the infections were healthcare- 
associated and MRSA accounted for nearly one third of S. aureus bacteraemias, clearly 
hospital infection control would be an important area for future clinical and microbiological 
research if improvements were to be made.
Significant delays in receiving effective antibiotic therapy were seen with MRSA 
bacteraemia compared with MSSA bacteraemia. Vancomycin was available in the study 
hospital but was not used in the empiric regimen for a patient with suspected bacterial 
sepsis unless they were already known to be MRSA positive. Delays in treating S. aureus
77
bacteraemia are known to have an adverse effect on outcome. 186 In light of the finding 
that 53% of S. aureus bacteraemia cases in the under 1 year old age group were MRSA 
and all MRSA strains were resistant to gentamicin, the routine usage of ampicillin plus 
gentamicin as empirical therapy for all children in that age group should be revised. 
Although alternative antibiotics to vancomycin may be appropriate therapy for MRSA, in 
the study setting the high rates of resistance found on susceptibility testing indicate that 
these alternatives would not be effective. A quarter of the patients with normal renal 
function were under-dosed for vancomycin, which is liable to lead to a poorer outcome. 
Monitoring of vancomycin levels was not possible at Sappasithiprasong Hospital, which 
may have led doctors to give lower doses to reduce the perceived risk of toxicity.
This study has demonstrated that S. aureus is a significant pathogen in northeast 
Thailand, with comparable clinical manifestations and a similar endocarditis prevalence 
but higher mortality than industrialised temperate countries. The factors contributing to this 
high death rate, such as the early management of sepsis, require further evaluation. The 
majority of infections were associated with exposure to healthcare settings and MRSA 
was associated with a considerable burden of disease and a high mortality. Revisions to 
the empiric prescribing practices to include MRSA therapy could be associated with 
significant benefit. An initiative to raise the profile of infection control is needed, together 
with work to characterise the burden and causes of hospital-acquired infections, including 
patient-to-patient transmission of MRSA, such that cost-effective solutions can be devised 
that are appropriate to this setting.
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Chapter 6. Prospective study of the applicability of the ‘Surviving Sepsis Campaign’ 
guidelines in a resource-restricted setting
6.1 Chapter content
Supportive sepsis care is an essential aspect of management for severe infections if 
deaths are to be prevented. An evaluation of the high mortality rate of S. aureus 
bacteraemia found in the prospective study, as discussed in Chapter 5, needs to consider 
the role of supportive sepsis care. The ‘Surviving Sepsis Campaign’ international 
guidelines for the management of severe sepsis and septic shock were first published in 
2004339 and were then updated in 2008.340 These guidelines describe best practice for 
clinical care in resource-rich settings and have been very influential in improving 
outcomes from sepsis in the developed world. The extent to which it would be possible to 
follow these guidelines in a resource-restricted tropical setting has not previously been 
determined at the time of writing. This chapter assesses the feasibility of determining the 
presence of severe sepsis and septic shock, and the extent to which the management of 
patients with severe sepsis and septic shock caused by S. aureus bacteraemia in a large 
provincial hospital in Thailand could follow the ‘Surviving Sepsis Campaign’ guidelines. 
The study hospital had not adopted the guidelines prior to or during the study.
6.2 Results
6.2.1 Hospital resources
The study hospital has 1,100 beds and serves a population of around 2 million people 
living in the province of Ubon Ratchathani, where the major occupation is rice farming. 
The hospital facilities include a range of routine laboratory and radiology services 
including a CT scanner. General medical, surgical and orthopaedic wards are 
predominantly open-plan and contain around 30 beds per ward, increasing up to 60 beds 
per ward in response to demand. There are 13 separate intensive care units (ICU) (each 
with between 8 and 14 beds), of which 4 are for paediatric patients and 9 are for adults. 
The registered nurse to patient ratio on the general wards is approximately 1:8 and is
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1:2.5 -1:3.5 on the ICUs. Mechanical ventilation is available in these ICUs; children and 
adults may be ventilated by electrically powered multi-function ventilators (e.g. Bear Cub, 
Infant Star, or Bennett). Patients on the general ward are commonly ventilated by older 
gas driven ventilators (Bird Mark 7).
6.2.2 Sepsis definitions
Children were defined as 18 years of age or less in keeping with paediatric sepsis 
classification.301 The standard sepsis definitions299'301 were adopted: sepsis was systemic 
inflammatory response syndrome (SIRS) associated with infection, which in this study was 
clinically significant S. aureus bacteraemia; severe sepsis was SIRS with organ 
dysfunction, sepsis-induced hypotension, or hypoperfusion, as denoted by oliguria or 
acidosis; septic shock was SIRS with sepsis-induced hypotension and/or the use of 
vasoactive drugs. As described in Chapter 5, there were 98 patients with S. aureus 
bacteraemia enrolled in the study, of whom 88 patients (90%) met the standard definition 
for sepsis (Tables 6.1 and 6.2). From the available data and adapted criteria shown in 
Tables 6.1 and 6.2, a total of 73 patients (49 adults) had severe sepsis, of whom 48 
patients (31 adults) had septic shock. The usual inclusion of hypotension despite 
adequate fluid resuscitation was not possible because of the format of documentation by 
treating physicians. Although arterial blood gases were available for 15 patients it was not 
possible to calculate the fraction of inspired oxygen, used to determine respiratory 
dysfunction, as inspired oxygen levels were not recorded.
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6.2.3 Patient characteristics
Since the ‘Surviving Sepsis Campaign’ guidelines target severe sepsis, the characteristics 
of the 73 patients with severe sepsis are considered in detail and shown in Table 6.3. The 
age ranged from 2 days to 92 years (median 48 years); 24 (33%) patients were children.
A history of any chronic underlying medical condition was documented in 47 cases (64%), 
with cardiac disease accounting for the greatest proportion. An identified site of infection, 
beyond bacteraemia, was found in 46 (63%) patients. MRSA was responsible for infection 
in 19 patients (26%).
6.2.4 Mortality
At 12-week follow-up, the mortality rates from severe staphylococcal sepsis overall or for 
the subset with septic shock were 58% and 65%, respectively. The majority of deaths 
(86%) occurred in hospital or at home on the day of discharge, as it is common for 
moribund patients to be taken home to die by their family. The 12-week mortality rate for 
severe sepsis from MRSA was 68% compared with 54% for MSSA (p=0.30). The median 
time to death for patients with severe sepsis was 3 days (IQR 1-9), and for the subset with 
septic shock was 2 days (IQR 1-4).
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Table 6.3: Characteristics of 73 patients with severe staphylococcal sepsis
Patients (n=73)
number of patients (%)
Demographics
Age (years) 48 (12 -  66)*1
Sex (male) 57 (58%)
Thai nationality*2 72 (99%)
Co-morbidities
Prematurity/ Very low birth weight 3(4)
Underlying medical conditions 47 (64)
- Cardiac disease*4 17(23)
- Renal disease*5 10(14)
- Diabetes mellitus 9(12)
- Immunosuppression*6 7(10)
- Lung disease*7 4(5)
Source and sensitivities
Community-acquired disease 35 (48)
Healthcare-associated disease 10(14)
Hospital-acquired disease 28 (38)
MRSA*6 19 (26)
Types of disease
0 identified sites of infection (bacteraemia alone) 27 (37)
1 identified site of infection, beyond bacteraemia 36 (49)
More than 1 identified site of infection, beyond bacteraemia 10(14)
Sites of infection*9 All sites (n=57)
number of sites (percent)
Skin and soft tissue infections 14 (25)
Pneumonia 10(18)
Device-related infections*10 8 (14)
Endocarditis*11 5(9)
Septic arthritis 5(9)
Post-operative mediastinitis*12 3 (5)
Other lung infections*13 3(5)
Solid organ abscess*14 3(5)
Osteomyelitis 2(4)
Pyomyositis 2(4)
Diabetic foot infections 1 (2 )
Urinary tract infection 1 (2)
*1 Median (interquartile range)
*2The one non-Thai patient was from Lao PDR
*3 Past medical history of any underlying chronic medical conditions reported by the 
patient and or relative, or recorded in the medical notes
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*4 Cardiac disease includes congenital heart disease (n=3), valvular heart disease (more 
than mild impairment) including rheumatic heart disease (n=7), ischaemic heart disease 
(n=4) and arrhythmias including heart block requiring a pacemaker (n=3).
*5 Renal disease incorporates end stage renal failure on chronic hemodialysis (n=2) and 
chronic renal failure secondary to diabetes mellitus (n=5), multiple myeloma (n=1), 
systemic lupus erythematosus (n=1) and unknown aetiology (n=1).
*6 Immunosuppression from chemotherapy (n=4), untreated leukaemia (n=1), HIV (n=1, 
not on anti-retroviral therapy) or immunosuppressive medication including prednisolone 
more than 30mg per day for more than 1 week (n=2, including 1 patient also on 
chemotherapy).
*7 Lung disease comprises previous tuberculosis (n=2), previous empyema (n=1) and a 
long term tracheostomy (n=1).
*8Methicillin-resistant S. aureus
*9 Since some patients had more than 1 site of infection, the denominator for this section 
is the number of sites (n=57)
*10 Device-related infections were intravenous catheters (n=4; central n=2, peripheral n=1, 
umbilical n=1), pacemakers (n=3) and an arteriovenous graft (n=1)
*11 Endocarditis from transthoracic echocardiographic evidence of vegetations (n=5)
*12 Post-operative following mitral valve replacement (n=3)
*13 Other lung infections included empyema (n=1), septic emboli to the lungs (n=1) and 
lung abscesses (n=1)
*13 Solid organ abscesses were liver (n=2) and spleen (n=1)
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6.2.5 Sepsis management
Overall, 27 of 73 patients (37%) received care in an ICU and the remainder were treated 
on a general ward; 13 children (54%) and 14 adults (29%) were treated in an ICU 
(p=0.04). The ICUs ran at full occupancy and access for adults was strongly influenced by 
bed availability. Of the patients who were admitted to an ICU, 21 (78%) had septic shock 
and 19 died (70%), in comparison to those patients cared for only on a general ward 
(n=46) of whom 27 (59%) had septic shock and 23 died (50%).
The extent to which the sepsis management of the 73 patients with severe sepsis 
or septic shock can be assessed against the ‘Surviving Sepsis Campaign’ guidelines is 
provided in Table 6.4. The details of patient management during the first 3 days after the 
first positive culture was taken are discussed below in a style that follows the format of 
Tables 3, 4, and 5 in the 2008 ‘Surviving Sepsis Campaign’ guidelines.340
86
Ta
ble
 
6.4
: 
Su
m
m
ar
y 
of 
se
ps
is 
m
an
ag
em
en
t
(/>
0
c
75
T3
'5
05
05
‘0
o .
E
re
O
0
w
Q .
a>
CO
05
c
■>
'E
3
CO
0
££
1  5x : o
-t-« t
{2 0
Cl
C  T3
■£ 0
>■ 3  
Q . CO 
CC 0
2  0
o |
©  3
£= o
£  ©  
ro 0
E  ©  
§  -©
0
T3 .i
0 05
_  0 0 
o  - 05  
0  CC C  W t -  
•=,0 0 
©> 0 >  
©  0  O  
CD 0  O
0  O  
0 5  CO 
C  i_ 
0 0 
>  
o  
0 
■O
o
3  =
CC 
x  
o
■O ■=
— o
0  LO-4-»
.55 6  
•O o
0  CO
E  *- 
E  °C/5
c  2  
.2 ©
S  JS
—  0 ^o  
0  
3  O
0 , 
0
I I
4 -  g -  
o  c
0 5  x :
©  £  
CD . 2
0 «4—»
0
x  0•+-« i_
0  3  O 0 — 0 
CC 0
o  .<5
0  0
>  -c
0 © «- r -
s « 
0 ©  
0 E
C L 0  
O  '
0
O
0 5
c
o
0 4—«
o
0
3
0
0i_
0
0
.> *
3
O
x
•4—>
3
Q .
3
O
0
c
0
0
©  C
*0 0
0 ~
© 0 
C  .h=
E
"O
0
"  E=  0 
cc Q- 
4= o  
c  Q  
0o 0•4—»
.E  "o
E  ©  0 c
Q - —  
•§ 8
E  x  
0 © 
0 o
. £  0
X  oQ. 0 
0 0 . 
X  0  X
‘5 .  Q . 2
© 0*0
n  ©  “  ©  0  XZ > o
0
x
0
Q .
0
0
0
0
0
0
o  ©  -*-■ _a
0 5 ‘X
E  2
o ’?x  
x  o
g - e
b  ro 
0 © 0 *o
05 X  
0
x  
0  
05  
>> 
X
o  
0  ‘S  
x  °
©  £  
-  2  
©  3  
3  0  
05 ©
0 2  
a : a .
x
o
0
X
0
05
>
X
o
0
E
+->
C L
O
0
>
0
X
o
0
o
■O
x
0
0
0
E
_3
O
>
75
■g
05
X
x  
o
05,
0
0
05
0  4~»
2  ■+->
0
0 
>  * x :  0
O  0
©  ^  3
O  0  
o  ©O - 0
0 5  q _
3  
—  0  
0  
0
ID 0
o
o  ^  
» “
j i  
*-* - -  
Q .
0
C/3
0  .©  
© as-sw' <4-10 3 
* -  Os ■*=
C/3 s
0
i2
c
.©■3
0
Q_|
H -
O
L.
0
•o
5
3
C
00
Q. c 
0 0 
0  - x  
a) 0  
l. a 
0 _
©  0  
C/3
00
00
, —s CM
o <4—o o"X— , ■
3
00 O
CM 00
CM
CM
CM
o
^  m
00 7=5 CO05 © CM
2  o 05
05
05
CO
CO
CD
CO
CM
CO
CO CO CO
lO
CO
CO
o'
CM
CM 05 g
05,
m
0
0 
o  ■
o  
0 
o  
0 -  0 
=> >
0
0 1_
CL
o
0
0
>
0
0
x
0
0 5
>4
Xo
x
0
0 5
> .
X
o
01©
C  to
cx  E  0 
o  O  ro
~  Q . ~
£  £  C  © 3 0
E  CO >
h -
00

6.2.5.1 Initial resuscitation and infection issues
(i) Initial resuscitation. Since patient recruitment followed blood culture results, initial 
resuscitation data was collected retrospectively. Additionally, given that the ‘Surviving 
Sepsis Campaign’ guidelines had not been adopted by the hospital, documented timing of 
initial resuscitation measures was not made.
(ii) Diagnosis and isolating the pathogen causing the episode of sepsis. The recruitment 
criteria of S. aureus bacteraemia meant all study patients had at least one blood culture 
taken. Two or more blood cultures were acquired in 10 of 73 patients during initial 
assessment. Almost all patients (96%) had radiological imaging performed.
(iii) Antibiotic therapy. A broad-spectrum intravenous antibiotic was received by 66 
patients (90%) on the day that the first positive blood culture was taken, and all but one of 
the remainder received a broad-spectrum antibiotic 24 hours or more later. The exact 
timing of the initial antibiotic dose was not recorded so no assessment can be made of the 
proportion of patients receiving their initial antibiotic within the first hour after recognition of 
severe sepsis. The infecting isolate was susceptible to the empiric antibiotic used in 54 
cases, but not in 15 cases infected with MRSA. Once culture results were available, 
almost all patients who were still alive (49 out of 50, 98%) received an antibiotic that 
covered their strain of S. aureus. Of the 12 patients with normal renal function receiving 
vancomycin, 8 (67%) received adequate vancomycin doses by manufacturer’s 
recommendations. Serum vancomycin levels were not tested because this assay was not 
available.
(iv) Source identification and control. A specific anatomical site of infection was identified 
in 46 patients, of whom 15 patients (33%) had a procedure contributing to infectious 
source control (abscess drainage 6 , debridement 5, joint wash-out 1, fasciotomy 1, above 
knee amputation 1, chest drain insertion 1). A further 5 patients had a potentially 
drainable collection of pus identified or infected prosthetic material but did not undergo a 
procedure as this was deemed unfeasible.
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6.2.5.2 Haemodynamic support and adjunctive therapy
(i) Fluid therapy. A documented fluid challenge using crystalloids was received by 19 
patients (26%), all of whom had septic shock. The volume given ranged from 150 to 
250mls in adults. Peripheral intravenous catheters alone were used in 61 of 73 patients 
(84%), cut-downs in 8 patients (7 adults and 1 child) and centrally placed catheters in 4 
patients (all children). Central venous pressure (CVP) readings were recorded in 6 
patients with cut-downs, all of whom had septic shock. A urinary catheter was inserted in 
37 patients (51%).
(ii) Vasopressors and inotropic therapy. Invasive monitoring of arterial pressure by an 
intra-arterial catheter was only possible in the cardiothoracic wards, and none of the 
patients in this study had this performed. All blood pressure measurements were made 
using cuffs. One or more vasoactive drugs were used in 28 out of 48 patients (58%) with 
septic shock and dopamine was most often used as the first line agent. The majority of 
patients receiving vasopressors or inotropes (69%) received the drug through a peripheral 
line.
(iii) Steroids and activated protein C. Steroids were not used in the context of sepsis, and 
recombinant human activated protein C was not available.
6.2.5.3 Other supportive therapy of severe sepsis
(i) Blood product administration. Red blood cell transfusions were given in response to 
lowered haemoglobin but were targeted to a haemoglobin greater than 9mg/dl. Since 
central or mixed venous saturations were not measured, red blood cell transfusions were 
not used to achieve a haematocrit of 30% in order to reach the saturations target.
(ii) Mechanical ventilation. A total of 36 out of 73 patients (49%) were ventilated. Of these, 
22 (61%) patients were ventilated using the Bird Mark 7 model (16 on a general ward, 6 in 
an ICU) of whom 2 (9%) survived (both in an ICU), and 14 were ventilated using 
electrically powered mechanical ventilators, of whom 4 (29%) survived (all in an ICU). At 
least one arterial blood gas was recorded in 12 of the 36 patients who were ventilated,
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while pulse oximetry measurements alone were used in 18 of these patients.
Supplemental oxygen was widely available.
(iii) Sedation, analgesia and neuromuscular blockade in sepsis. These are not part of 
routine care in adults or children. Sedation was used in children who did not otherwise 
tolerate mechanical ventilation. Adults ventilated on the general ward did not receive 
sedation.
(iv) Glucose control. Blood sugar monitoring was performed in 38 out of 73 patients 
(52%). Blood sugar control was achieved by intermittent point-of-care testing of capillary 
blood glucose and subcutaneous insulin.
(v) Renal replacement therapy. None of the patients with acute renal failure (n=18) or an 
additional 16 patients who were acidotic received any form of dialysis because in the 
setting of sepsis these were not indications for acute dialysis in the hospital.
(vi) Deep vein thrombosis prophylaxis and stress ulcer prophylaxis. These were not part of 
routine care and were not given.
6.3 Discussion
The burden of sepsis in developing countries is massive but grossly understudied in 
comparison to developed parts of the world. This study of severe staphylococcal sepsis is 
among the first to quantify prospectively the management and outcomes of patients with 
sepsis in a developing country setting. The mortality rate in this study is double the all­
cause severe sepsis mortality rates reported from developed countries.502'505 This 
emphasises the need for concerted efforts to improve sepsis care in developing regions of 
the world. With only slight modifications to the standard criteria for determining organ 
dysfunction, it was feasible to ascertain the proportion of patients with severe sepsis and 
septic shock within the current resource capability of the hospital. A hospital policy to 
routinely document inspired oxygen levels for those patients having arterial blood gases 
samples taken, and Glasgow Coma Scores in sick patients would further improve the 
hospital physicians’ ability to detect organ dysfunction. This is fundamental because
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recognition of sepsis and its severity is an essential prerequisite to activating the 
appropriate sepsis management required.
Many basic resources are available in developing countries for the management of 
patients with severe sepsis and septic shock. Microbiology laboratory facilities are critical 
because knowledge of the causative organism facilitates the utilisation of disease-specific 
measures and antimicrobial therapy can be tailored according to the susceptibility profile. 
The choice of empiric antibiotic therapy covered S. aureus less than 75% of the time, 
although this largely reflected the hospital policy to only prescribe vancomycin for culture- 
confirmed MRSA. The majority of patients had radiological imaging performed and 75% of 
those with a pus collection identified underwent a procedure for infectious source control. 
The guidelines caution that investigations to obtain a diagnosis and infectious source 
control procedures should only be carried out when safe to do so, in particular since 
investigations and procedures that require transporting the patient away from an ICU have 
considerable risks even in developed countries. Many of the patient cohort were critically 
ill which hampered the ability of physicians to fully work up their patients. An important 
limitation of this study is that the patient cohort was biased towards those with potential 
disease-specific measures who would be predicted to have a better outcome by 
examining only staphylococcal sepsis as opposed to all-cause sepsis (which includes 
patients without an identified causative organism).
Certain more complex sepsis management therapies such as invasive 
haemodynamic monitoring, ventilation and dialysis are available in some developing 
countries. Fluid resuscitation in septic patients is challenging, even in developed countries 
with widespread use of invasive haemodynamic monitoring. Crystalloid intravenous fluids 
were widely available in the hospital, but patients with sepsis including those with septic 
shock received low volumes of fluids. This may have been due to concerns about 
precipitating volume overload because bedside observations and fluid balance records 
were the mainstay of assessing volume status, and acute dialysis in the context of sepsis 
was not available. Respiratoryfailure was often managed with mechanical ventilation. 
However, outcomes following institution of mechanical ventilation were uniformly poor. In
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particular, all patients ventilated on the general ward died. Mechanical ventilation may 
simply serve as a marker for critically ill patients. This strongly suggests that focussing 
sepsis management on the underlying disease process is essential to prevent a 
progression towards respiratory failure. Although some more complex interventions may 
be available in developing country settings, if their use is not associated with a survival 
benefit, as in the case of mechanical ventilation on the general ward in this study, then 
their continued use should be carefully considered. Further study of the utility and cost- 
benefit of specific therapies that are more complex and expensive in these settings is 
needed.
It is likely that these findings would be reproduced in a large number of medical 
facilities throughout the developing world. Thus, there is an urgent need to develop 
methods to optimise sepsis care within the existing framework and resources of such 
settings. A workable strategy should focus on the basic elements of sepsis care, namely 
appropriate sampling for diagnostic microbiology, rapid antibiotic administration, adequate 
infusion of intravenous fluids and control of the infectious source. These core elements 
are likely to comprise much of the benefit in the treatment of sepsis. Initiating such a 
strategy is within the capability of large numbers of hospitals throughout the world, can be 
implemented without prohibitive expense, and has the potential to save many thousands 
of lives per year. Such an approach would if successfully implemented represent an 
important step for global health and a move away from the current narrow focus on care of 
patients in developed countries. Efforts to raise the profile of sepsis have been successful 
in developed countries but there remains a pressing need for both education of healthcare 
providers and comprehensive research into sepsis in developing countries. These 
endeavours are the next essential components of a strategy to tackle the mortality burden 
of sepsis worldwide.
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Chapter 7. Methicillin-resistant S. aureus (MRSA) carriage and transmission study 
results
7.1 Chapter content
At the time of writing, there are no published studies from Thailand on MRSA 
carriage or transmission, and data from South and East Asia are limited. Given the 
significant burden of disease caused by MRSA in Thailand and the high associated 
mortality as described in Chapters 3-6, it is highly relevant to determine the extent of 
MRSA colonisation and factors contributing to nosocomial transmission in this setting. The 
purpose of this study was to establish the prevalence of MRSA carriage in specific 
hospital settings, and to generate data to inform infection control strategies to reduce 
MRSA transmission and infection.
Two Intensive Care Unit (ICU) wards at Sappasithiprasong Hospital were chosen 
for the study. This choice was informed by two observations. First, ICUs in Europe are 
known to have higher MRSA carriage rates than general wards.403,506,507 Second, these 
wards had harboured patients with MRSA bacteraemia in the previous prospective clinical 
study (Chapters 4-6). The study methods were as described in Chapter 2.
7.2 Ward details
The study wards were a general paediatric ICU, and an adult surgical ICU that provided 
care to patients with gastroenterological conditions, especially gastrointestinal 
haemorrhage. The paediatric ICU had 7 beds and 7 cots in open plan (Figure 7.1) and 
admitted children aged from 1 month to 15 years. The bed occupancy rate during the 
study period was 91%. The distance between the cots and beds ranged from 47cm to 
199cm (median distance 109cm). There were 3 hand washing basins spaced around the 
ward. The surgical ICU had 8 beds in open plan (Figure 7.2). The bed occupancy rate 
during the study period was 102%. The distance between beds ranged from 57cm to 
72cm (median 63cm). There were 2 hand washing basins at one end of the ward.
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There were no isolation facilities on either ICU. Alcohol handrub was available at 
the end of each bed on both study ICUs. Disposable gloves and masks were readily 
available but aprons were not used. In the study hospital disposable gloves are collected, 
sterilised on site and then re-used multiple times until they break. Gloves were used for 
wound care and procedures involving bodily fluids. The patient to nurse ratio on the study 
ICUs was 1.3-1.8 . Screening for MRSA carriage was not performed on any ward in the 
study hospital before the start of the study. Patients with MRSA infections cannot be 
isolated, due to an absence of isolation facilities, but are moved to one end of the row of 
beds in the ward if possible. These patients are not allocated a specific nurse.
7.3 Infection control
The study hospital has an infection control policy and an infection control team overseen 
by a doctor and 2 senior nurses. The responsibility for infection control on each ward is 
allocated to a member of the ward nursing staff who liaises with the 2 senior nurses. 
Infection control is included in the hospital’s teaching programme for the nursing staff. The 
hospital diagnostic microbiology laboratory informs the senior nurses responsible for 
infection control if any cultures grow MRSA or extended spectrum beta-lactamase 
resistant gram-negative pathogens, who then investigate for a potential outbreak.
7.4 Results
7.4.1 Patient characteristics
Surgical ICU: a total of 182 patients were present at the start of the study or admitted over 
the 3 month study period, of whom 173 patients were enrolled. Nine patients could not be 
studied because they declined consent (n=6) or they died or were discharged from the 
study ward before consent could be obtained (n=3). Of the 173 patients enrolled, 1 patient 
declined any further swabs following the first set.
Paediatric ICU: a total of 126 patients were present at the start of the study or 
were admitted during the study period, of whom 106 patients were enrolled. Nineteen 
patients could not be studied because their relatives declined consent (n=8), were
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discharged from the study ward before consent could be obtained (n=10) or there was a 
language barrier for obtaining consent (n=1). In 1 further case the patient’s guardian gave 
consent but the child refused to be swabbed and was then discharged from the study 
ward; this case was excluded from any analysis.
The patient characteristics for each ward are given in Table 7.1. In keeping with 
the admission policies of the study wards, the patients on the surgical ICU were aged 15 
to 93 years (median 62 years, interquartile range (IQR) 49-73 years) and those on the 
paediatric ward were aged 1 month to 15 years (median 2 years, IQR 8 months -  10 
years). There was a significant predominance of male patients on both the surgical and 
paediatric ICU wards (68% p<0.001 and 60% p=0.04, respectively). The most common 
diagnoses for the paediatric patients were: respiratoryfailure (40%, n=42), sepsis (20%, 
n=21) and seizures (13%, n=14). On the surgical ward patients were commonly admitted 
with gastrointestinal haemorrhage (43%, n=75); other reasons for admission included: 
post-operative care following abdominal or retroperitoneal surgery (24%, n=42), septic 
shock (12%, n=20) and peritonitis (6%, n=11).
The pattern of admissions to the study ICU wards was quite different between the 
paediatric and adult wards, as detailed in Table 7.1. The turnover of patients was 
significantly more rapid on the surgical ICU (median length of stay for the first admission 2 
days (IQR 1-4) versus 3 days (IQR 2-7), p=0.009). For those patients already admitted to 
the study ward prior to the onset of study enrolment, the length of time on the study ward 
before enrolment was significantly longer for the paediatric patients than the surgical 
patients (median length 31 days (IQR 6-76) versus 3 days (IQR 1-10), p=0.02), which was 
in keeping with the longer lengths of stay on the paediatric ward. The difference in the 
numbers of patients already on the study ward at the start of enrolment between the 2 
ICUs merely reflects the discrepancy in the number of beds on each unit. Paediatric 
patients also had significantly more repeat admissions to the study ICU than the adult 
surgical patients (p<0 .001).
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Table 7.1: Patient characteristics for the 2 Intensive Care Unit (ICU) study wards
Surgical ICU ward 
(n=173)
Paediatric ICU ward 
(n=106)
Age median (IQR) 62 years 
(49-73 years)
2 years 
(8 months-10 years)
Sex (male) number (% of 
ward total)
118(68%) 64 (60%)
1st Admission to study ICU
On ICU ward at start 
of study
- Length of inpatient 
stay before study
number (% of 
ward total) 
median (IQR)
7 (4%)
3 days (1-10 days)
13(12%)
31 days (6-76 days)
Inpatient at study 
hospital prior to ICU 
- Length of inpatient 
stay before ICU
number (% of 
ward total)
median (IQR)
87 (50%)
1 day (0-2 days)
49 (46%)
1 day (0-8 days)
Direct admission to 
study ICU 
- Admitted from 
another health centre
number (% of 
ward total)
79 (46%) 
70/79 (89%)
44 (42%) 
36/44 (82%)
Length of stay during 
3 month study period
median (IQR) 2 days (1-4 days) 3 days (2-7 days)
2nd Admission to study ICU
Number of patients 
with 2nd admission
number (% of 
ward total)
4 (2%) 15(14%)
Length of hospital 
admission between 
1st and 2nd ICU 
admission
range; ’1 
median (IQR)
0-4 days 8 days’2 
(6-15 days)
Length of stay during 
3 month study period
range; *1 
median (IQR)
1-12 days 2 days 
(1-22 days)
3rd Admission to study ICU
Number of patients 
with 3rd admission
number (% of 
ward total)
0 3 (3%)
Length of hospital 
admission between 
2nd and 3rd ICU 
admission
range 0-42 days’3
Length of stay during 
3 month study period
range 3-25 days
4th Admission to stud y ICU
Number of patients 
with 4th admission
number (% of 
ward total)
0 1 (1%)
Length of hospital 
admission between 
3rd and 4th ICU 
admission
1 day
Length of stay during 
3 month study period
14 days
*1 First column (i.e. Surgical ICU) shows range because there are only 4 data points and 
second column (i.e. Paediatric ICU) shows median (IQR).
^2  patients discharged home for 2 and 15 days respectively in the interval between their 
1st and 2nd ICU admissions
43 1 patient discharged home for 36 days in the interval between their 2nd and 3rd ICU 
admission
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7.4.2 Patient carriage and transmission
On the adult surgical ICU ward, 75 of the 173 patients (43%) were positive for S. aureus 
on at least one screening swab, 27 of which were MRSA (16% of patients admitted to the 
unit during the study period). On the paediatric ICU, 63 of 106 patients (59%) were 
positive for S. aureus on at least one screening swab, 33 of which were MRSA (31% of 
patients admitted to the unit during the study period). The difference in MRSA carriage 
rates between the two units was highly significant (p=0.003).
A detailed breakdown of the results of the differing swabs and other samples is 
shown in Table 7.2. Initially taking the results from the whole patient cohort, on both the 
adult surgical ICU and the paediatric ICU tracheal suction samples detected the highest 
proportion of MRSA carriers. Predictably, wound swabs were taken significantly more 
frequently on the surgical ICU, with at least one wound swab taken from 51% versus 11% 
of all patients, respectively (p<0.001). Urine samples were taken significantly less 
frequently on the paediatric ICU, 8% versus 93% of all patients, respectively (p<0.001), as 
young children wore nappies rather than being catheterised. Amongst patients carrying 
MRSA, nasal swabs were the most common swab type to be positive, followed by throat 
swabs and tracheal samples with 2nd and 3rd place differing between the 2 wards. Urine 
samples had the lowest rate of positivity for MRSA amongst both the adult and paediatric 
patients.
Amongst the patients carrying MRSA, the paediatric patients had more screens 
performed compared to the adult surgical patients, 3 screens (IQR 2-4) versus 4 (IQR 3- 
9), respectively (p=0.05) and a significantly greater number of positive screens, 1 screen 
(IQR 1-3) versus 3 (IQR 1-7), respectively (p=0.04). There was a trend for the paediatric 
patients to have a higher proportion of patients with more than 50% of screens positive for 
MRSA compared with adult surgical patients, 73% versus 48% respectively (p=0.065). 
These results are likely to reflect the longer lengths of stay and higher number of re­
admissions amongst the paediatric patients.
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The characteristics of MRSA carriage and acquisition are shown in Table 7.3. On 
the surgical ICU over half the patients (56%) acquired MRSA whilst they were admitted to 
the study ward. A third of the patients arrived on the ward for the first time during the study 
as MRSA carriers. Over half (52%) the patients only had one screen positive for MRSA 
and the majority of these involved 1 swab that grew MRSA. By comparison, on the 
paediatric ICU equal numbers of patients acquired MRSA whilst they were admitted to the 
study ward as arrived on the ward for the first time during the study as MRSA carriers. 
More than half (58%) the paediatric patients carried MRSA continuously, once acquired, 
and 2 of the 3 patients who intermittently carried MRSA had 24 or more positive screens. 
The proportion of patients who acquired MRSA on the study ward during the study period 
was not significantly different between the 2 ICUs (p=0.19) nor was the pattern of MRSA 
carriage (p=0.36). The median time to MRSA acquisition from admission to the study 
hospital was significantly shorter on the surgical ICU, 4 days (IQR 3-6 days) versus 11 
days (IQR 2-17 days) (p=0.013). However, the median time to MRSA acquisition from 
admission to the study ICU was not significantly different between the surgical and 
paediatric ICUs, 3 days (IQR 1-4 days) and 2 days (IQR 1-9 days) respectively, (p=0.76). 
On both study ICUs the majority of patients had received antibiotic therapy prior to the 
detection of their MRSA. Of the 9 patients (4 surgical, 5 paediatric) who “cleared” their 
MRSA 6 (2 surgical, 4 paediatric) had only one screen negative for MRSA prior to 
discharge from the study ICU so some of these cases may in fact reflect intermittent 
carriage.
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Table 7.3: Characteristics of MRSA carriage and acquisition
Characteristic Surgical ICU 
MRSA cases (n=27)
Paediatric ICU 
MRSA cases (n=33)
MRSA acquisition
MRSA first detected from:
- 1st screen 11 (41%) 17 (52%)
- 2nd screen 12 (44%) 8 (24%) ^
- 3rd screen 2 (7 % f 4 (12%)'"
- 4th screen 1 (4%) 2 (6%)
- 5th screen 1 (4%) 1 (3%)
- 10th screen - 1 (3%)
MRSA acquired
- Before start of study if on ward at 
start of study
(1st screen of study detected MRSA)
2 (7%) 5(15%)
- Before arrival on study ward 
(1st screen detected MRSA)
9 (33%) 12 (36%)
- On study ICU ward during study 
period
15 (56%) 12(36%)
- On another ward in hospital
(1st screen of re-admission to study 
ward detected MRSA)
1 (4%) 4(12%)
On ward at start of study (n=2) (n=11) 
median (IQR)
- Days in study hospital prior to first 
MRSA detected
15 and 22 days 47 (17-90) days
- Days on study ICU prior to first 
MRSA detected
1 and 5 days 4 (0-9) days
Admission during study (n=25) 
median (IQR)
(n=22) 
median (IQR)
Days in study hospital prior to first 
MRSA detected
4 (3-6) days 11 (2-17) days
- Days on study ICU prior to first 
MRSA detected (adjusted for time 
between study ICU admissions)
3 (1-4) days 2 (1-9) days
Antibiotic therapy received prior to first 
MRSA screen
24 (89%) 29 (88%)
MRSA carriage
One positive screen only 14 (52%) 11 (33%)
1 swab from screen grew MRSA 10 9
- 2 swabs from screen grew MRSA 4 2
Intermittent carriage
(all swabs of one screen negative
between two positive screens)
2 (7%) 3 (9%)
Continuous carriage
(at least one swab in every screen
positive)
11 (41%) 19 (58%)
“Clears” MRSA
(all swabs of screen negative prior to 
discharge from study ward)
4 (14%) 5(15%)
103
Data are number (%), unless otherwise specified
*1 In 1 of these cases it was the 1st screen after re-admission to the study ICU 
*2 In 2 of these cases it was the 1st screen after re-admission to the study ICU 
*3 In 2 of these cases it was the 1st screen after re-admission to the study ICU
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7.4.3 Isolate antibiogram profiles and sequence types
The majority of MRSA isolates were multi-resistant in vitro to the panel of antibiotics 
tested as shown in Table 7.4. Combined resistance to ciprofloxacin, clindamycin, 
erythromycin, gentamicin, netilmicin, tetracycline and trimethoprim-sulphamethoxazole 
was seen in 94% of isolates. The first MRSA isolate obtained for each patient, with 
preference given to nasal samples, underwent molecular analysis to determine the 
sequence type. Of these initial MRSA isolates 97% (58/60) were sequence type 239 (ST 
239). In those 5 patients who carried MRSA intermittently, the first MRSA swab after a 
screen of all negative swabs was also genotyped and all were ST 239. By sequence type 
these subsequent isolates were unchanged from the original isolate for that patient, 
however by antibiogram the isolate had changed in 4 out of 5 patients (Table 7.5), 
although only by 1 antibiotic in each case.
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Table 7.4: Antibiotic resistance rates from in vitro disk diffusion testing
Antibiotic Resistance rate
Cefoxitin 100%
Chloramphenicol 2%
Ciprofloxacin 99%
Clindamycin 98%
Erythromycin 100%
Fusidic acid 23%
Gentamicin 99%
Mupirocin 33%
Netilmicin 98%
Penicillin 100%
Rifampicin 21%
Tetracycline 99%
T rimethoprim-sulphamethoxazole 99%
Vancomycin 0%
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7.4.4 MRSA infection
Amongst the 33 patients on the paediatric ICU who carried MRSA, 2 developed MRSA 
bacteraemia (6%). In each case their MRSA carriage was detected prior to the isolation 
from blood cultures. Although the isolates from bacteraemia were not obtained for further 
re-testing their antibiograms from the hospital diagnostic microbiology laboratory matched 
those of the carriage strains. Whilst there was no MRSA detected from blood cultures on 
the surgical ICU, 53 patients (31%) had temperatures recorded £38°C from whom no 
cultures were taken.
7.4.5 Nursing staff
Covert hand washing surveys on each of the wards showed that compliance was 0-17% 
(mean 9%) on the surgical ICU and 0-14% (mean 8%) on the paediatric ICU. On the 
surgical ICU, 22 nursing staff were screened and 1 nurse was found to carry MRSA on a 
nasal swab on a single screen. The nurse was not screened again because by chance 
she was not on duty the next 2 times screening was undertaken. From the 15 nursing staff 
screened on the paediatric ICU, 4 were colonised with MRSA; 1 from finger imprints and 3 
from nasal swabs. The nurse with the hand carriage was not a nasal carrier on a single 
screen and again by chance was not on duty the next 2 times screening was undertaken. 
Amongst the 3 nurses with nasal carriage, one was a persistent nasal carrier with positive 
nasal swabs from all 3 screenings; the others were not screened after their MRSA positive 
swab but one of these 2 had been screened previously and had not grown MRSA. There 
was a significant association between length of time working and carriage status: the 
nurses colonised with MRSA had worked for a shorter length of time than those not 
carrying MRSA, 7 years (IQR 4-8 years) compared with 12 years (IQR 8-19 years), 
p=0.04. There was a trend which did not reach significance between MRSA colonisation 
and the seniority of the different nursing grades in Thailand (p=0.07); all the MRSA 
carriers were registered nurses, who are more senior than technical nurses which is the 
grade above nurse aide. All of the nurses worked full time.
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7.5 Discussion
This study of MRSA carriage has clearly demonstrated that acquisition and transmission 
of MRSA within the study ICUs was occurring at a considerable rate. However, MRSA 
carriage and transmission did not appear to be solely an issue on the ICUs; 5 patients re­
admitting to study ICUs were found to be MRSA carriers for the first time. It was not 
possible from the study design to determine how many patients who were on the ward 
prior to the start of the study or who were admitted to other wards in the hospital before 
the study ICUs, had acquired MRSA on other hospital wards. The rate of MRSA carriage 
was significantly higher on the paediatric ICU, where the patients’ length of hospital and 
ICU stays and number of ICU admissions were significantly higher. Increasing length of 
hospital stay as a risk factor for the development of MRSA carriage has been established 
in developed countries401,403’405 and the findings of this study would support this as a risk 
factor in a developing country setting. The median time to acquisition of MRSA after 
admission to the study ICU was rapid on both the paediatric and surgical ICUs, 2 and 3 
days respectively. This meant that even though the turnover of patients on the surgical 
ICU was high (median length of stay 1 day), there was a considerable rate of MRSA 
carriage. There was a high input pressure of patients arriving on the ward already carrying 
MRSA, which would facilitate the rapid dissemination amongst the other ICU patients. 
Additionally, the antibiotic pressure was high with almost 90% of patients receiving 
antibiotic therapy before their MRSA carriage was detected.
The multi-resistant nature of the in vitro antibiotic resistance profiles of the MRSA 
carriage isolates and the fact that they belonged to a single clone of ST 239 supported the 
notion that these were healthcare-associated. ST 239 is known to be the dominant MRSA 
clone causing hospital-acquired infection in Thailand224 and is the predominant clone 
across South and East Asia.508 Although CA-MRSA is a considerable problem in many 
countries and more recently has begun to contribute to MRSA transmission within 
healthcare facilities,509'512 this was not a feature of this study. The similarity of the carriage 
isolates was a limiting factor of the study because establishing the epidemiology of 
transmission in more detail from the current data was not possible. A typing technique,
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such as pulsed field gel electrophoresis, might provide some insights into variability within 
the ST 239 clone which could be used to study transmission dynamics in greater detail.
Since hand washing compliance rates were poor on both ICUs, MRSA 
transmission from patient-to-patient via healthcare worker hands was likely to have been a 
major contributor to the high carriage rates observed. The finding that nurses who were 
MRSA carriers had a significantly shorter length of time spent working as a nurse could 
reflect the duties of nurses of differing experience. For example, newer nurses may have 
to perform more duties involving bodily fluids, which is a task known to be associated with 
a higher rate of contamination. Lack of experience could correlate with lower hand 
washing compliance, although all the MRSA carriers were registered nurses and in 
Thailand registered nurses receive the longest training of the 3 nursing grades.
The lack of interest in and concern with MRSA carriage and transmission as 
developing country problems, as demonstrated by the scarcity of published literature, 
seems unjustified in light of this study. Rates of MRSA carriage up to 31% demand urgent 
attention. The poor hand washing compliance indicates that hand washing is an essential 
aspect of infection control to target and could be achieved largely without additional 
expense. Further measures, such as increasing the space between beds, isolation rooms 
for patients with MRSA, increasing the number of hand wash basins on the wards or 
disposing of and not re-sterilising gloves require considerable additional investment in 
resources. Studies to specifically assess the cost-effectiveness of such expensive 
interventions would be needed prior to implementation. Addressing MRSA carriage is of 
major importance because patients are most likely to develop an infection with their own 
carriage strain,54,56 so patients carrying MRSA are at a higher risk of MRSA infection, from 
which the mortality is often higher than MSSA.513'515 There were 2 patients on the 
paediatric ICU who developed MRSA bacteraemia following MRSA carriage, representing 
6% of all the MRSA carriers on that ward over a short time period of this study (3 months).
The World Health Organisation is promoting hand hygiene as their first global 
patient safety challenge, under the campaign “Clean care is safer care”.474 Although 
Thailand has pledged its commitment to addressing healthcare-associated infections, a
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number of other countries in South and East Asia, including neighbours of Thailand, have 
not yet signed up to this WHO initiative. Drug-resistant bacteria are not constrained by 
country borders and so tackling healthcare-associated infections, including MRSA, 
requires a concerted international effort in order to succeed.
111
Chapter 8. Concluding comments
For many clinicians and researchers around the world, S. aureus is not a pathogen of 
particular relevance to the tropics. A review of the literature on S. aureus in resource- 
restricted countries in South and East Asia to assess this assumption threw up more 
questions than answers. A major question was whether the lack of published studies was 
due to a low prevalence of S. aureus disease in this region, or more likely based on 
anecdotal experience in resource-restricted Asia, that lack of resources including 
diagnostic microbiology facilities led to under-representation in the literature. This body of 
work convincingly demonstrates that in provincial Thailand at least, S. aureus is 
responsible for substantial morbidity and mortality. It is improbable that this is an isolated 
finding because the published literature includes S. aureus as one of the causative 
organisms for a diverse range of clinical manifestations from countries across the Asian 
region. Further work is needed from more resource-restricted countries in South and East 
Asia to determine the full extent of the disease burden due to S. aureus. Hopefully the 
publication of this body of work will encourage other researchers to consider this as a 
topic for future study.
A further consideration is whether S. aureus behaves differently in a tropical 
climate, perhaps causing less severe disease, a factor that could contribute towards the 
lack of published data. However, the work contained in this thesis establishes that with 
regard to epidemiology, risk factors for disease and clinical presentations, S. aureus in the 
tropical developing country studied mirrors that of temperate developed countries. S. 
aureus commonly caused invasive disease and severe sepsis amongst those with 
bacteraemia which refutes the suggestion of a less virulent pathogen. The finding that the 
mortality rate for S. aureus bacteraemia was much higher in provincial Thailand than in 
developed countries again does not support a hypothesis that S. aureus is less virulent in 
this setting.
Mortality from sepsis is a global problem but disproportionately affects developing 
countries. Whilst major steps in improving supportive sepsis management have been
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made in developed countries, in large part due to the ‘Surviving Sepsis Campaign’ 
guidelines, outcomes in developing countries remain very poor. The findings from this 
work that many of the essential elements, namely appropriate sampling for diagnostic 
microbiology, adequate fluid resuscitation, prompt antibiotic therapy and procedures for 
infectious source control, are within the capability of resource-restricted health centres are 
very encouraging. Work on adapting these sepsis guidelines and implementing them in a 
broad variety of resource-restricted health settings in developing countries across the 
world is urgently needed. Research funding bodies placing their support behind such a 
strategy would be invaluable.
The acquisition of antibiotic resistance by important pathogens is a high profile 
concern in developed countries. This work describing the considerable rates of MRSA in 
bacteraemia and the higher mortality rates attributable to MRSA indicates that this issue is 
just as relevant in a resource-restricted setting. Given the challenges faced by developed 
countries in tackling drug resistance even when access to antibiotic is regulated, 
meaningful progress on drug resistance in developing countries is unlikely to be achieved 
unless there is political will to control and regulate antibiotic availability and to address the 
manufacturing and distribution of sub-standard antibiotic drugs.
The debate over whether Panton-Valentine Leukocidin (PVL) is a virulence 
determinant and its potential mode of action remains controversial and hotly contested. 
This work adds importantly to the evidence because it describes results in an unselected 
cohort of patients, which has been distinctly lacking in the literature to date. The finding 
that PVL gene-positive isolates were associated with survival was unexpected and 
challenges the current epidemiological support for its role in virulence.
The work on MRSA carriage and transmission within 2 Intensive Care Units 
highlights that MRSA carriage is an endemic problem of considerable magnitude. Urgent 
infection control interventions are clearly required. The most basic and inexpensive 
infection control measure is hand washing and this study revealed that there was much 
room for improvement on compliance rates. An obvious follow on study would be to
113
determine the effectiveness of a hand washing campaign on MRSA carriage rates and 
infections.
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Appendix 1. Retrospective Staphylococcus aureus Study Form
Study number ________________
Ubon Ratchathani hospital number  ___________
Patient Information
Last name First name
Date of Birth  I I  Age _______
Gender: Male Female
Occupation:_______________________________
Hospital Admission Information
Admit Date  I__ I____
Discharge Date  I_____ I____
Community vs hospital-acquired infection
Positive blood culture taken within 48 hours of admission Yes No
Healthcare contact in last year? Yes No
Details of attendance (use code)
Source Information
Initial source of infection (give code)______________________________________
Was surgery performed within previous 30 days of infection at the site of this surgery? 
Yes No
If yes, what type of surgery was performed?________________________________
If yes, when was the surgery performed? / /
Prosthesis present at time of infection Yes No
Give code of type of prosthesis__________________________ _________________
Removable source of bacteraemia present Yes No 
Was a removable focus removed? Yes No
Number of days from 1st blood culture positive for S. aureus until removal of removable 
source __________ days
Past Medical History
Chronic illness (give all relevant codes please)_______________________________
Is the patient allergic to penicillin? Yes No
165
Blood Culture Information
Date of first positive blood culture for S. aureus / /
White cell count at time of 1st positive blood culture __________________x 109/L
Number of blood cultures drawn (starting with 1st blood culture positive for S. aureus):_ 
Number of blood cultures positive (starting with 1st blood culture positive for S. aureus):
Do the blood cultures meet Duke major criteria? Yes No
Do the blood cultures meet Duke minor criteria? Yes No
Blood Cultures
Date # drawn # Positive MSSA/MRSA
/ /
/ /
/ /
/ /
/ /
/ /
/ /
Temperature >38°C continued to be recorded >72 hours after1st blood culture positive for
S. aureus? Yes No
No. of days after 1st blood culture positive for S. aureus before effective antibiotic therapy 
started? days
Complications
Metastatic infection is defined as a site of S. aureus infection resulting from spread from 
an initial site (via bloodstream seeding or direct extension).
Metastatic infection Yes No
Give infection code and for each infection give code for confirmation:_____________
Echocardiogram performed? Yes No
Date Echocardiogram performed / /
Echo result (give codes)__________________
Duke Major echocardiographic criteria met? Yes No
Duke Minor echocardiographic criteria met? Yes No
Heart Valve Information
Has the patient had a previous episode of infective endocarditis (IE)? Yes No
Does the patient have a known cardiac condition that predisposes to endocarditis?
Yes No If yes, code of disease: _______________________________
Does the patient have a prosthetic valve present? Yes No
Which valve(s) (give codes)?______________________
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Which type of valve (give code)?______________________
Treatment
Was the patient receiving antibiotic therapy at time blood culture taken? Yes No
Which antibiotics?  ___________________________________________________
Which antibiotics were used after 1st blood culture positive for S. aureus? ________
How many days in total of antibiotic therapy were received? _______ days
How many days of effective antibiotic therapy were received? _______ days
Outcome
Give outcome code:_______ ________
If the outcome was death, when did the patient die? / /
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Codes for form
Healthcare contact codes
1. In-patient stay
2. Out-patient appt
3. Attendance for regular interventions e.g. haemodialysis, blood transfusions, 
radiotherapy
Initial source of bacteraemia (choose one):
1 Abscess 9 Gangrene 17 Empyema
2 Cellulitis 10 Septic arthritis 18 Mediastinitis
3 Skin ulcer 11 Infected joint prosthesis 19 Sinusitis
4 Burn 12 Peripheral intravenous catheter 20 Percutaneous
nephrostomy
5 Wound -  trauma 13 Central intravenous catheter 21 Peritoneal dialysis
6 Wound -  surgical 14 Vascular graft 22 Biliary tract
7 Dermatitis/ psoriasis 15 Primary AV fistula 23 None/ unknown
8 Furuncle 16 Pneumonia 24 Other
If “other” was chosen above, list the source:
Prosthesis Type
1. Short-term peripheral intravenous catheter/cannula
2. Short-term central intravenous catheter/cannula
3. Indwelling peripheral intravenous catheter/cannula e.g. PICC line
4. Indwelling central intravenous catheter/cannula e.g. Hickman line
5. Intravascular graft
6. Haemodialysis graft
7. Prosthetic heart valve
8. Pacemaker/ defibrillator
9. Joint replacement
10. Orthopaedic rod/ plate/ screws
Chronic illness codes
1. Severe lung disease e.g. chronic obstructive pulmonary disease, emphysema, 
tuberculosis
2. Severe cardiac disease e.g. rheumatic heart disease, ischaemic heart disease
3. Severe liver disease e.g. chronic hepatitis C, auto-immune liver disease
4. Chronic renal failure
5. Dialysis-dependent
6. Diabetes mellitus
7. Lymphoma or leukaemia
8. Received radiotherapy or chemotherapy
9. Currently on immunosuppressive therapy, including high dose steroids
10. Recipient of an organ transplant
11. Immunosuppressed e.g. HIV infection
Metastatic infections
A. Endocarditis
B. Lung emboli
C. Brain emboli
D. Septic arthritis
E. Osteomyelitis
F. Glomerulonephritis
Confirmed by
1. Physical examination
2. Culture
3. Radiology
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4. Echocardiography
5. Other
Echo result 
Valve(s) involved:
A. Mitral valve
B. Aortic valve
C. Tricuspid valve
D. Pulmonary valve
Defects seen:
1. More than mild regurgitation
2. Valve prolapse
3. Thickened valve leaflet
4. Prosthetic valve
5. Vegetation
6. Calcified valve
7. Perforated valve
8. Paravalvular abscess
9. Ruptured chordae
Predisposing heart conditions for endocarditis
1. Rheumatic heart disease
2. Congenital heart disease
Place of prosthetic valve
A. Mitral valve
B. Aortic valve
C. Tricuspid valve
D. Pulmonary valve
Type of prosthetic valve
1. Metallic valve
2. Tissue valve
3. Ring/ support device
Outcome
1. Cure
2. Complications of S. aureus (haematogenous seeding)
3. Death due to S. aureus
4. Death due to other causes
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Prospective study of invasive Staphylococcus aureus disease -  Data collection sheet
Please fill in the blanks or circle the appropriate choices.
Study number __________
Ubon Ratchathani hospital number
Date of 1 visit / /
Patient Information
First name Last name
/ /Date of B ir th ____________
Gender: Male Female
Occupation:_____________
Phone numbers: home 
Address:
Age
ID card number
mobile
Hospital Information
Admit Date
Discharge Date
/ /
/ /
Ward
Time
Time
Consultant
Place
Details on admission/ when culture taken
Date 1st positive culture for S. aureus taken
On that date:
Maximum temperature °C
Did the patient have a significant BP abnormality (i.e. systolic ^90, diastolic <60)? 
Yes No N/A
Maximum pulse  bpm
Maximum respiratory rate _______bpm
White cell count at time 1st positive culture taken 
date / /
x 109/L
Procedure
Was a procedure used to treat the staphylococcal infection? 
Date / /
Yes No
Surgical debridement Abscess drainage (l+D)
Surgical removal of graft/ prosthesis Joint wash out (arthrocentesis)
Other,
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investigations
Investigations performed to look for presence of pus collections? Yes No
Date Investigation Result
Treatment
When was antibiotic treatment started? /  /
When was antibiotic treatment finished? / /
Empirical antibiotic therapy: Ideal Staph cover Covers Staph but not ideal Does 
not cover Staph
Date effective antibiotic therapy started /  /
Antibiotic regimen:
Antibiotic given Start date Stop date Route Dose and frequency No. of days
How many days in total were antibiotics used?
Reason vancomycin therapy used:
MRSA
Suspected MRSA
Penicillin Allergy
Inappropriate (None of above reasons apply)
How many days elapsed from starting effective intravenous antibiotic therapy until the day 
when maximum temperature <38°C?_________
On what date did the patient defervesce*? I I Was it within 72 hours?
Yes No N/A
*(Temperature consistently <38 °C and remains <38 °C.)
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Symptom Information
Number of days before culture taken that the patient first had any symptoms or signs?
admission ______________
History:
Fever Yes No Infected skin lesion Yes No
Chills and Sweats Yes No Chest pain Yes No
Malaise Yes No Cough with sputum Yes No
CNS involvement Yes No Abdominal pain Yes No
Haematuria Yes No Joint pain Yes No
Skin changes (e.g. petechiae) Yes No Muscle pain Yes No
Shortness of breath Yes No Neonates -  poor feeding Yes No
Peripheral oedema Yes No Neonates -  maternal mastitis Yes No
Past Medical History
Significant lung disease e.g. COPD Yes No Recipient of organ transplant Yes No
Significant cardiac disease e.g. IHD, Yes No Currently on immuno­ Yes No
rheumatic disease suppressive therapy, inc high 
dose steroids (>30mg/day)
Significant liver disease e.g. Hep C Yes No Lymphoma or leukaemia Yes No
Chronic renal failure Yes No Other cancer Yes No
(creatinine >200pmol/L; >2mg/dL)
Dialysis-dependent Yes No Received radiotherapy or 
chemotherapy
Yes No
Diabetes mellitus Yes No HIV infection Yes No
Rheumatoid arthritis/ osteoarthritis Yes No On HAART Yes No
Other significant condition not mentioned above?________________________________
Is the patient allergic to penicillin? Yes (details:______________________ ) No Not known
Heart Valve information:
Has the patient had a previous episode of infective endocarditis (IE)? Yes No
Does the patient have a known cardiac condition that predisposes to endocarditis?
Yes No (Rheumatic heart disease/ congenital heart disease)
Does the patient have a replacement valve present? Yes No
Valve(s): Mitral Aortic Tricuspid Pulmonary
Type of valve: Metallic valve Tissue valve Ring/ support device
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MRSA risk factors
Healthcare contact in last year? Yes No
In-patient stay
Hospital type: Local/District Ubon Other e.g. BKK_____________
Dates of most recent stay______________________________________
□ 2-3 in-patient stays in last year □ >3 in-patient stays in last year
Out-patient visits
Clinic/ intervention: OPD Dialysis Chemotherapy Radiology Other_______
Frequency: weekly every 1-2 months/ 3-4 months/ 5-6 months/ >6 months
As a relative
OPD/ single visit Stayed overnight Multiple visits to ward 
Other MRSA risk factors1
Resident of care/nursing home Yes No IVDU (current or ever) Yes No
Healthcare worker Yes No Household contact of IVDU Yes No
Household contact of healthcare Yes No Prison in last year Yes No
exposure
Close contact of similar infection Yes No Household contact of prison Yes No
exposure
Antibiotics taken in last month Yes No Living on streets in last year Yes No
Antibiotics taken for this infection Yes No Competitive contact sport in Yes No
last month
Presence of wounds/ skin breaches Yes No
1 Moran GJ et al NEJM 355(7): 666-674
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Physical Examination at time of 1st positive S. aureus culture result
Patient continues to have a temperature >38°C? Yes No Maximum temp °C
Examination findings
Skin Normal Yes No Pustule/abscess Yes No
Petechiae Yes No Cellulitis Yes No
Macules/ Janeway lesions Yes No Ulcer Yes No
Osier’s nodes Yes No Infected cannula site Yes No
Vasculitis lesions/infarcts Yes No Infected wound site Yes No
Ecchymosis Yes No Infected graft site Yes No
Other Yes No
Nails Normal Yes No Infected Yes No
Splinter haemorrhages Yes No
Other Yes No
Murmur None Yes No New Murmur Yes No
Systolic Yes No Signs of heart failure Yes No
Diastolic Yes No
Other Yes No
Resp Normal Yes No Signs of effusion/ Yes No
empyema
Signs of pneumonia Yes No CXR confirms examination Yes No
Other Yes No
Gl Normal Yes No Hepatomegaly Yes No
Splenomegaly Yes No Tenderness Yes No
Other Yes No
Neuro Normal Yes No Visual field defect Yes No
Focal neurological signs in Yes No Meningitis signs Yes No
limbs
Confusion/ reduced GCS Yes No
Other Yes No
Joints Normal Yes No Erythematous Yes No
Swelling Yes No Reduced range of Yes No
movement
Tenderness Yes No Inability to weight-bear Yes No
Other Yes No
Neonate Normal Yes No Umbilicus site clean Yes No
Jaundice Yes No Vaccination sites okay Yes No
Skin rash Yes No
Other Yes No
Prosthesis present at time of infection Yes No
In-hospital peripheral 
intravenous cannula
In-hospital central intravenous cannula e.g. cut 
down
Out-of-hospital peripheral 
intravenous cannula e.g. 
heparin lock
Out-of-hospital central intravenous cannula e.g. 
double lumen
Intravascular graft or stent Haemodialysis graft
Prosthetic heart valve Pacemaker/ defibrillator
Joint replacement Orthopaedic rod/ plate/ screws
Peritoneal dialysis catheter Other
Removable source of bacteraemia present Yes No
If present, was removable focus removed? Yes No
Date of removal / /_____
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Cultures
Date of repeat study culture / / Result:
Number of cultures taken (starting with 1st culture positive for S. aureus): ______
Number of cultures positive (starting with 1st culture positive for S. aureus):______
If blood cultures positive, do they meet Duke major criteria? Yes No
If blood cultures positive, do they meet Duke minor criteria ? Yes No
Cultures
Date No. taken Specimens taken No. positive MSSA/MRSA
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
Source and site of Infection
Community-acquired admission to hospital with an illness consistent with invasive
S. aureus disease
Hospital-acquired positive S. aureus culture taken >48 hours after admission for
another condition
Was surgery performed within previous 30 days of infection at the site of a previous
surgery? Yes No
If yes, what type of surgery was performed?
If yes, when was the surgery performed? _____/_____/
Source of infection:
1 Cutaneous abscess/ pustule 5 Open skin lesion 9 Surgery
2 Injection 6 Penetrating injury 10 Unknown
3 Intravenous device 7 Phlebotomy 11 Unknown, probable 
i.v. device
4 Other prosthetic material 8 Respiratory tract 12 Other
Details of “other” or other “prosthetic material”
Site/ type of infection:
1 Abscess 9 Other skin lesion 17 Blood
2 Cellulitis 10 Diabetic foot infection 18 Contaminant
3 Furuncle/ pustule 11 Osteomyelitis -  non vertebral 19 Empyema
4 Gangrene 12 Osteomyelitis -  vertebral 20 Endocarditis
5 Infected burn 13 Pyomyositis 21 Mediastinitis
6 Skin ulcer 14 Septic arthritis 22 Meningitis
7 Wound -  surgical 15 Peritonitis 23 Pneumonia
8 Wound -  trauma 16 Pyelonephritis 24 Other
Type of abscess___________________________
If “other” or “other skin lesion” was chosen above, details:
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Echo information
Has a TTE been done? Yes No If yes, when? / /
Height________cm Weight________ kg
Defects seen Mitral valve Aortic valve Tricuspid
valve
Pulmonary
valve
More than mild 
regurgitation
Valve prolapse
Thickened valve leaflet
Prosthetic valve
Vegetation
Calcified valve
Perforated valve
Paravalvular abscess
Ruptured chordae
Other findings:
Duke Major echocardiographic criteria met? Yes No
Duke Minor echocardiographic criteria met? Yes No
Was vegetation seen by TTE? Yes No
Vegetation width (mm)   Vegetation length (mm) ________
Metastatic Sites of Infection
Metastatic infection is defined as a site of S. aureus infection resulting from spread from 
an initial site (via bloodstream seeding or direct extension).
Metastatic infection Yes (Y) No (N) Suspected (S)
Metastatic
infection
Y/N/S Culture Imaging Suspected
from
examination
Other
details
Abscess
Arthritis
Epidural abscess
Endocarditis
Kidney abscess
Meningitis*
Vertebral
osteomyelitis
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Non-vertebral
osteomyelitis
Psoas abscess
Septic emboli
Septic
thrombophlebitis
Other
* Confirmed if positive CSF culture; suspected if raised WBC, high protein, low glucose
Follow-up
Follow-up date / / How?
Details:
Outcome
Outcome Definitions
Cure Clinically improved, negative repeat culture, no 
additional sites of infection suspected or found
Unresolved infection/ 
Treatment failure
Persistent fever, a new focus of infection that 
developed during treatment or persistent bacteraemia
Death due to S. aureus During admission or within 12 weeks of 1st positive 
culture for S. aureus
Death due to other causes During admission or within 12 weeks of 1st positive 
culture for S. aureus
If the outcome was death, when did the patient die? / /
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Daily progress notes
Date, time Notes Signed
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Additional sepsis data
Date of 1st S. aureus culture: / /
Study number
/ / / I / /
AM PM AM PM AM PM
Temp
HR
BP
RR
In: iv
In: oral
Out: urine
Out: other
□ SIRS (2/4) Temp £38C or <36C HR >90 beats/min RR >20 breaths/min 
WCC >12 x103/pl or <4 x103/pl or >10% immature band forms
FBC: WCC________ _103/(j| Band form % Hct________% Hb________g/dl
RBC transfusion: Yes/ No Volume transfused:_____________ ___________________
Renal failure: BUN______(7-18 mg/dL) C r______ (0.6-1.3 mg/dL) Date _ _ / _ _ / _
BUN_____ (7-18 mg/dL) C r______ (0.6-1.3 mg/dL) Date / /
Supplemental oxygen given: Yes/ No Nasal cannulae Mask Mask with bag
Ventilated: Yes/ No Bird Other ventilator:_______________________
0 2 monitoring: Yes/ No Sats only ABG
Septic shock: Yes/ No I/O record: Yes/ No Fluid bolus prescribed: Yes/ No 
Cut down: Yes/ No Central line: Yes/ No CVP readings: Yes/ No Catheterised: Yes/ No 
Vasopressors/ inotropes: Yes/ No Dose prescribed:____________________________
Cardiac arrest: Yes/ No
Coagulation: Plat 103/pl PT:____ (10-14 sec) INR:___ APPT:______(23-33 sec)
Liver failure: total bili________ (0-1 mg/dL) A lb______ (3.8-5.4 g/dL)
Diabetic: Yes/ No Blood sugar monitoring: Yes/ No Sliding scale: Yes/ No
Antibiotic therapy
MSSA
1st line: cloxacillin/ dicloxacillin/ approp cephalo (e.g. cefazolin, ceftriaxone, cefotaxime)
2nd line: augmentin/ clindamycin/ erythromycin/ imipenem/ sensitive Abx from testing 
Not best practice: gent/ ceftaz/ amikacin/ cipro/ fuscidic/ septrin/ roxithro/ doxy/ cefoxitin
MRSA
1st line: vancomycin 
2nd line: NA
Empiric: 1st/ 2nd/ Not Post-culture result: 1st/ 2nd/ Not
Polypharmacy: Yes/ No Max. no. of antibiotics simultaneously:____________
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MRSA carriage study: Data collection sheets -  Patients
Study number:_______ HN: _ _ _ _________  Ward: PICU 2 ICU surgery 2
Name:______________________________________  Bed no.________
Age: years Sex: Male Female
Hospital admission date: / / ; time________admitted from
ICU admission date: / / ; time_______ admitted from___
Reason for ICU admission:__________________________________
ICU discharge date: / / time_______ discharged to ____
Hospital discharge date: / / Died: Yes/ No/ Discharged moribund
discharged to ____________
Antibiotic therapy _______________________________________________________
Antibiotic given Start date Stop date Route Dose and frequency No. of days
Procedures
Date On ward/ OR Procedure
Investigations for infections
Date Investigation Result
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Culture resul ts (non-study)
Date No. taken Specimens taken No. positive Organism
Details on development of hospital-acquired infection (S. aureus or other):
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Samples information Study no.
Admission Discharge Day 3 Day 7 Day 10 Day 14
Date
Axilla (A)
Result
Tracheal
(C)
Result
Nasal (N)
Result
2 swabs?
Reason
Throat (T)
Result
Urine (U)
Result
Wound
(W)
Result
Site
Wound
Result
Site
Wound
Result
Site
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Results continued Study no.
Day Day Day Day Day Day
Date
Axilla (A)
Result
Tracheal
(C)
Result
Nasal (N)
Result
2 swabs?
Reason
Throat (T)
Result
Urine (U)
Result
Wound
(W)
Result
Site
Wound
Result
Site
Wound
Result
Site
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MRSA carriage study: Data collection sheets -  Nursing staff
Study number:______________
Name:____________________________________
Age:___________ years Sex: Male Female
Number of years working as a nurse:______________ years
Role:_________________________________ __________
Ward: PICU 2 ICU surgery 2
Samples information 
Nasal swabs
1st screen 2nd screen 3rd screen
Date taken
Swab number
Culture result MSSA MRSA 
Neither
MSSA MRSA 
Neither
MSSA MRSA 
Neither
Hand agar imprints
Dominant hand: Left Right
1st screen 2nd screen 3rd screen
Date taken
Agar plate number
Culture result MSSA MRSA 
Neither
MSSA MRSA 
Neither
MSSA MRSA 
Neither
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